  Clinical Study Protocol 
    BTCRC-LUN17-127  
 
 
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung 
Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127 
 
Sponsor Investigator 
Salma Jabbour, MD  
Rutgers Cancer Institute of New Jersey 
 
 
Co-Investigator 
Jyoti Malhotra, MD, MPH 
City of Hope 
 
 
Statistician 
Dirk Moore, PhD 
 
 
Trial Management  
Big Ten CRC Administrative Headquarters at Hoosier Cancer Research Network, Inc. 
7676 Interactive Way, Suite 120 
Indianapolis, IN 46278 
 
 
Trial Support 
BeyondSpring Pharmaceuticals, Inc.: BPI-2358-203 
Bristol-Myers Squibb (drug only): CA209-8CF 
 
Investigational New Drug (IND) Number: 
139651 
 
 
 
Initial Protocol Version Date: 05JUN2018  
 
Protocol Amendment Version Date:  
15JAN2019  
14JAN2020  
03MAR2021  
27APR2022 (current) 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 2 of 77 PROTOCOL SIGNATURE PAGE 
 
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in  
Patients with Recurrent Small Cell Lung Cancer 
 
 
VERSION DATE:  27APR2022 
I confirm I have read this protocol, I understand it, and I will work according to this protocol and to the 
ethical principles stated in the latest version of the Declaration of Helsinki, the applicable guidelines for 
good clinical practices, whichever provides the greater protection of the individual.  I will accept the 
monitor’s overseeing of the study.  I will promptly submit the protocol to applicable ethical review 
board(s). 
 
 
 
 
____________________________________ ________________________ 
 Signature of Site Investigator       Date 
 
 
____________________________________ 
 Site Investigator Name (printed) 
 
 
____________________________________ 
 Site Investigator Title 
 
 
____________________________________ 
 Name of Facility 
 
 
____________________________________ 
 Location of Facility (City and State) 
 
 
 
PLEASE EMAIL COMPLETED FORM TO  
BIG TEN CRC ADMINISTRATIVE HEADQUARTERS 
 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 3 of 77 SYNOPSIS  
TITLE A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients 
with Recurrent Small Cell Lung Cancer  
PHASE  Phase I/II 
OBJECTIVES Primary: 
Phase I: 
The primary objective of the Phase I dose escalation study is to establish the 
maximum tolerated dose (MTD) of plinabulin in combination with 
nivolumab and ipilimumab for patients with recurrent SCLC. 
Phase 2: 
The primary objective of the Phase II, single-arm study is to determine if the 
addition of plinabulin to double checkpoint inhibition (PD-1 and CTLA-4) 
for recurrent SCLC will improve progression-free survival (PFS, the time 
from treatment assignment to the date of the first documented tumor 
progression, or death due to any cause, whichever occurred first). 
Secondary: 
 To assess toxicity and tolerability of the combination of nivolumab, 
ipilimumab and plinabulin. 
 To measure the frequency of immune-related adverse events 
(irAEs). 
 To determine the proportion of patients with a confirmed objective 
response in the Phase II part (defined as the number of patients with 
a best overall response of complete response or partial response 
divided by the number of assigned patients). 
 To estimate clinical benefit rate (CBR: complete response, partial 
response, or stable disease). 
 To estimate 6-month (± 4 weeks) PFS. 
 To estimate overall survival (OS) and 1-year OS. 
Exploratory:  
 To measure biomarkers of inflammation (high sensitivity C-reactive 
protein [hsCRP], erythrocyte sedimentation rate [ESR], serum 
amyloid A [SAA]) and haptoglobin  
 To correlate tumor mutational burden with PFS and ORR 
 To measure biomarkers of activity such as immune cell phenotypes, 
TCR-seq and circulating cytokines and to correlate with PFS and 
ORR. 
STUDY DESIGN This is an open-label Phase I/II study, with a dose escalation part (Phase I) 
and a single-arm Phase II, in patients with recurrent SCLC. 
In the Phase I part, patients will receive plinabulin at escalating doses in 
combination with nivolumab and ipilimumab. Doses of study drug will be 
administered as intravenous (IV) infusions in 21-day cycles. Patients will 
receive all study drugs on Day 1 of each cycle. After 4 treatment cycles, 
ipilimumab is stopped and patients continue treatment with nivolumab and 
plinabulin every 2 weeks (maintenance period) or until disease progression, 
development of unacceptable toxicity or one of the protocol-defined reasons 
for treatment discontinuation occurs.  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 4 of 77 At least 3 patients will be enrolled in each cohort, starting at 20 mg/m2 of 
plinabulin. The dose of plinabulin will be escalated in sequential patient 
cohorts after the safety data from the first cycle is reviewed. Thereafter the 
dose of plinabulin will be escalated to 30 mg/m2, provided that dose-limiting 
toxicities (DLTs) are not observed per the specified criteria, until the RP2D 
is determined. 
In the Phase II part, up to 26 patients will be treated with the triple 
combination of plinabulin (at RP2D) + nivolumab + ipilimumab. Patients 
will continue treatment until disease progression, development of 
unacceptable toxicity or one of the protocol-defined reasons for treatment 
discontinuation occurs.  
KEY ELIGIBILITY 
CRITERIA  1. Must have signed and dated written informed consent form in accordance 
with regulatory and institutional guidelines. 
2. Males and females aged >18 years at time of consent. 
3. Histological or cytological confirmed extensive-stage SCLC  
4. Patients who progressed after at least 1 platinum-based chemotherapy 
regimen. Patients with platinum resistance (defined as recurrence or 
progression of disease within 90 days of completion of the platinum-based 
regimen) are eligible. For phase II, patients must have been treated with at 
least one prior line of PD-1/PD-L1 therapy.  
5. Measurable disease according to RECIST v1.1 obtained by imaging within 
28 days prior to study registration. 
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 
within 14 days before registration and minimum life expectancy of at least 
12 weeks 
7. Treatment to be initiated at least 2 weeks since last dose of prior systemic 
anticancer therapy (chemotherapy, radiation, and/or surgery) 
8.  Recovery to grade 1 of any clinically significant toxicity (excluding 
alopecia, grade 2 fatigue, vitiligo, endocrinopathies on stable replacement 
therapy) prior to initiation of study drugs 
9. Female patients of childbearing potential have a negative pregnancy test at 
baseline. See Eligibility Criteria for complete guidelines. 
10. Adequate laboratory values. 
a. Absolute neutrophil count ≥1,000/µL. 
b. Platelet count ≥100,000/µL. 
c. Hemoglobin ≥9.0 g/dL. 
d. Total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for 
subjects with Gilbert’s disease  
e. ALT and AST ≤3.0 x ULN (≤5 x ULN if evidence of hepatic 
involvement by malignant disease). 
f. Creatinine ≤ 1.5 x ULN or estimated glomerular filtration rate ≥40 
mL/min/1.73m2. 
g. Lipase and amylase ≤1.5 x ULN. Subjects with lipase >1.5 x ULN may 
enroll if there are neither clinical nor radiographic signs of a 
pancreatitis. 
11. Must not have received previous CTLA-4 targeted therapy . 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 5 of 77 STATISTICAL 
CONSIDERATIONS  Sample Size 
For the Phase I part of the study, between 9 and 15 patients will be enrolled. 
For the Phase II portion of the study, PFS will be the primary outcome. The 
patients will receive nivolumab, ipilimumab and plinabulin. In previous 
studies, without plinabulin, the median survival with nivolumab and 
ipilimumab was 1.5 months. It is anticipated to be able to detect, with 80% 
power, an increase in PFS from 1.5 to 3.5 months (a 2 month increase), with 
a two sided 5% level test of survival. Assuming an accrual period of 
12 months and an additional 1 year of follow-up time, this increase could be 
detected by accruing 26. Patients who receive plinabulin at RP2D level in 
phase I dose-escalation will count towards the 26 patients and will be 
included in the efficacy analysis. 
Safety Endpoints 
The safety endpoints for this study are the incidence and severity of AEs and 
laboratory abnormalities, the occurrence of SAEs and treatment 
discontinuations due to AEs. 
Efficacy Endpoints 
Primary Efficacy Endpoint: 
 PFS in the Phase II part of the study. 
Secondary Efficacy Endpoints: 
 Objective response in the Phase II part of the study. 
 CBR: complete response, partial response, or stable disease. 
 6-month PFS. 
 OS and 1-year OS. 
Analysis Populations 
Safety Population: all patients who received at least 1 dose of plinabulin, 
nivolumab and ipilimumab and had at least 1 post-dose safety assessment. 
DLT Evaluable Population: all patients in the dose-escalation part who 
received 2 doses of plinabulin, nivolumab and ipilimumab. 
Efficacy Evaluable Population: all patients who received RP2D of plinabulin 
and met the following two criteria will be considered evaluable for efficacy: 
 patients who received at least 1 cycle of therapy 
 patients who had at least 1 on-study disease assessment or who 
developed early progression prior to the first planned on-study disease 
assessment.  
TOTAL NUMBER 
OF SUBJECTS Phase I: approximately 9-15 patients 
Phase II: up to 26 patients 
ESTIMATED 
ENROLLMENT 
PERIOD Phase I: 6-9 months 
Phase II: 12 months 
ESTIMATED 
STUDY 
DURATION  36 months 
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 6 of 77 TABLE OF CONTENTS 
 
List of Abbreviations  ................................................................................................................................ 8  
Phase I Schema ......................................................................................................................................... 10  
Phase II Schema ........................................................................................................................................ 11  
1. Background and Rationale ................................................................................................................ 12  
1.1 Rationale for the study .............................................................................................................. 12  
1.2 Plinabulin (BPI-2358, previously known as NPI-2358) ........................................................... 13  
1.3 Nivolumab................................................................................................................................. 17  
1.4 Ipilimumab ................................................................................................................................ 18  
1.5 Nivolumab and Ipilimumab Combination ................................................................................ 19  
1.6 Nivolumab, Ipilimumab and Plinabulin Combination .............................................................. 20  
2. Study Objectives and Endpoints ....................................................................................................... 21  
2.1 Objectives ................................................................................................................................. 21  
2.2 Endpoints .................................................................................................................................. 22  
3. Eligibility Criteria ............................................................................................................................. 22  
3.1 Inclusion Criteria ...................................................................................................................... 22  
3.2 Exclusion Criteria ..................................................................................................................... 23  
4. Subject Registration .......................................................................................................................... 25  
5. Study Design ..................................................................................................................................... 25  
5.1 Overview of Study Design ........................................................................................................ 25  
5.2 Phase I (Dose Escalation) ......................................................................................................... 25  
5.3 Definition of Dose-Limiting Toxicity ....................................................................................... 27  
5.4 Phase II...................................................................................................................................... 28  
6. Treatment Plan .................................................................................................................................. 28  
6.1 Phase I (Dose Escalation) ......................................................................................................... 28  
6.2 Phase II...................................................................................................................................... 28  
6.3 Vital Signs During Plinabulin Infusions ................................................................................... 29  
6.4 Allowed Concomitant Medications .......................................................................................... 29  
6.5 Supportive Care ........................................................................................................................ 30  
7. Toxicities and Dose Delays/Dose Modifications .............................................................................. 32  
7.1 Dose Delays/Dose Modifications ............................................................................................. 32  
7.2 Protocol Discontinuation .......................................................................................................... 41  
8. Calendar & Evaluations .................................................................................................................... 42  
8.1 Study Assessments and Procedures .......................................................................................... 44  
8.2 Screening Visit and Baseline (Within 28 Days Prior to Registration) ...................................... 44  
8.3 On Treatment Evaluations ........................................................................................................ 45  
8.4 Protocol Discontinuation and Assessment ................................................................................ 45  
8.5 Surgery or Radiation Therapy ................................................................................................... 46  
8.6 Safety Follow-up Evaluations ................................................................................................... 47  
8.7 Long Term Follow-up Evaluations ........................................................................................... 47  
9. Biospecimen Studies and Procedures ............................................................................................... 47  
9.1 Biomarkers of Inflammation and Cytokine Panels ................................................................... 47  
9.2 Tumor Mutation burden ............................................................................................................ 48  
9.3 Immunophenotyping/Immune Repertoire TCR Sequencing .................................................... 48  
9.4 Banking of Leftover Biospecimens .......................................................................................... 48  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 7 of 77 9.5 Samples for future unspecified studies ..................................................................................... 48  
9.6 Confidentiality of Biospecimens............................................................................................... 48  
10. Criteria for Disease Evaluation ..................................................................................................... 49  
10.1 Measurable Disease .................................................................................................................. 49  
10.2 Non-measurable Lesions ........................................................................................................... 49  
10.3 Target Lesions ........................................................................................................................... 49  
10.4 Non-target Lesions .................................................................................................................... 50  
10.5 Evaluation of Target Lesions .................................................................................................... 50  
10.6 Evaluation of Non-target Lesions ............................................................................................. 50  
10.7 Evaluation of Best Overall Response ....................................................................................... 51  
11. Drug Information .......................................................................................................................... 51  
11.1 Plinabulin .................................................................................................................................. 51  
11.2 Nivolumab (Opdivo®) .............................................................................................................. 53  
11.3 Ipilimumab (Yervoy™) .............................................................................................................. 54  
12. Adverse Events ............................................................................................................................. 56  
12.1 Definitions................................................................................................................................. 56  
12.2 Reporting................................................................................................................................... 57  
12.3 Site Requirements for Reporting Pregnancy to Big Ten CRC Administrative Headquarters .. 58  
13. Statistical Methods ........................................................................................................................ 60  
13.1 Study Design ............................................................................................................................. 60  
13.2 Endpoints .................................................................................................................................. 60  
13.3 Sample Size and Accrual .......................................................................................................... 60  
13.4 Analysis Populations ................................................................................................................. 61  
13.5 Assessment of Safety ................................................................................................................ 61  
13.6 Data Analysis Plans .................................................................................................................. 62  
13.7 Analysis Plans for Correlative/ Exploratory Objectives ........................................................... 62  
13.8 Interim Analysis/Criteria for Stopping Study ........................................................................... 63  
14. Trial Management ......................................................................................................................... 63  
14.1 Data and Safety Monitoring Plan (DSMP) ............................................................................... 63  
14.2 Rutgers Cancer Institute of New Jersey Data Safety Monitoring Committee .......................... 63  
14.3 Data Quality Oversight Activities ............................................................................................. 64  
14.4 Compliance with Trial Registration and Results Posting Requirements .................................. 64  
14.5 Protocol and/or Informed Consent Amendments ..................................................................... 64  
15. Data Handling and Record Keeping ............................................................................................. 64  
15.1 Data Management ..................................................................................................................... 64  
15.2 Case Report Forms and Submission ......................................................................................... 65  
15.3 Record Retention ...................................................................................................................... 65  
15.4 Confidentiality .......................................................................................................................... 65  
16. Ethics............................................................................................................................................. 65  
16.1 Institutional Review Board (IRB) Approval ............................................................................. 65  
16.2 Ethical Conduct of the Study .................................................................................................... 66  
16.3 Informed Consent Process ........................................................................................................ 66  
17. References ..................................................................................................................................... 67  
18. APPENDIX 1: Adverse Event Management Algorithms ............................................................. 69  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 8 of 77  
LIST OF ABBREVIATIONS 
5-HT3 5-Hydroxytryptamine Type 3 
ACTH Adrenocorticotropic Hormone 
AE Adverse Event 
ALT (SGPT) Alanine Aminotransferase 
AST (SGOT) Aspartate Aminotransferase 
BSA Body Surface Area 
CBC Complete Blood Count 
CI Confidence Interval 
CR Complete Response 
CT Computed Tomography 
CTCAE Common Terminology Criteria for Adverse Events 
DSMC Data Safety Monitoring Committee 
ECOG Eastern Cooperative Oncology Group 
eCRF Electronic Case Report Form(s) 
EDC Electronic Data Capture 
EGFR Epidermal Growth Factor Receptor 
ESR Erythrocyte Sedimentation Rate 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GI Gastrointestinal 
HIV Human Immunodeficiency Virus 
hsCRP High Sensitivity C-reactive Protein 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
IEC Institutional Ethics Committee 
IND Investigational New Drug  
INR International Normalized Ratio 
IRB Institutional Review Board 
ITT Intent-to-Treat 
IV Intravenous 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 9 of 77 LIST OF ABBREVIATIONS 
irAE(s) Immune-related Adverse Event(s) 
MedDRA Medical Dictionary for Regulatory Activities 
mg Milligram 
mL Milliliter 
MRI Magnetic Resonance Imaging 
NCCN National Comprehensive Cancer Network 
NCI National Cancer Institute 
NE Not Evaluable 
OR Objective Response  
OS Overall Survival 
PBMC Peripheral Blood Mononuclear Cell 
PD Progressive Disease 
PDE4 Phosphodiesterase Type 4  
PFS Progression-free Survival 
PR Partial Response 
RECIST Response Evaluation Criteria in Solid Tumors 
RP2D Recommended Phase 2 Dose 
SAA Serum Amyloid A 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SCLC Small Cell Lung Cancer 
T3 Triiodothyronine 
T4 Free Thyroxine 
TSH Thyroid Stimulating Hormone  
ULN Upper Limit of Normal 
US United States 
WBC White Blood Cell 
WHO World Health Organization  
  
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 10 of 77 PHASE I SCHEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Follow up every 3 months for 1 
year from end of treatment. 
N= up to 15 subjects 
Histological or cytological confirmed extensive-stage SCLC; 
Progressed after at least 1 platinum-based chemotherapy regimen 
Day 1, Cycles 1-4 
(cycle = 21 days) 
Nivolumab : 1 mg/kg 
Ipilimumab : 3 mg/kg 
Plinabulin :  
(-1) 13.5 mg/m2 
(start) 20 mg/m2 
(+1) 30 mg/m2 
Day 1, Cycles 5+ 
(cycle = 14 days) 
Nivolumab : 240 mg 
Plinabulin : as above  
CR, PR or SD 
Disease Assessment post Cycle 2, post Cycle 4, then every 4 cycles 
Progression or significant toxicity 
Continue treatment  
 Discontinue treatment. 
Big Ten Cancer Research Consortium    Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 11 of 77 PHASE II SCHEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow up every 3 months for 1 
year from end of treatment. 
N= 26 subjects* 
Histological or cytological confirmed extensive-stage SCLC; 
Progressed after at least 1 platinum-based chemotherapy regimen 
Nivo/Ipi/Plinabulin  
CR, PR or SD 
Disease Assessment post Cycle 2, post Cycle 4, then every 4 cycles 
Progression or significant toxicity 
Continue treatment  
 Discontinue treatment. 
Day 1, Cycles 1-4 
(cycle = 21 days) 
Nivolumab : 1 mg/kg 
Ipilimumab : 3 mg/kg  
Plinabulin : at RP2D 
 
Day 1, Cycles 5+ 
(cycle = 14 days) 
Nivolumab : 240 mg 
Plinabulin : at RP2D  
* Patients who receive plinabulin at the recommended phase 2 dose (RP2D) level in the phase I dose-
escalation will count towards the 26 patients. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 12 of 77 1. BACKGROUND AND RATIONALE 
1.1 Rationale for the study 
Lung cancer is the leading cause of cancer-related mortality worldwide. According to WHO Fact Sheet 
no 297, updated February 2017, lung cancer caused 1.69 million deaths in 2015. In the United States 
(US), approximately 415,000 Americans living today have been diagnosed with lung cancer at some 
point in their lives ( U.S. National Institutes of Health, 1975-2013 ). During 2016, an estimated 224,390 
new cases of lung cancer were expected to be diagnosed, representing about 13 percent of all cancer 
diagnoses ( Siegel et al 2016 ). Neuroendocrine tumors account for approximately 20% of lung cancers; 
most of which (approximately 14%) are SCLC. In 2017, an estimated 31,000 new cases of SCLC will 
occur in the US ( Siegel et al 2017 ). SCLC is characterized by a rapid doubling time, high growth 
fraction and early development of widespread metastases. Most patients with SCLC present with 
hematogeneous metastases; approximately one-third present with limited disease confined to the chest. 
SCLC is highly sensitive to initial chemotherapy and radiotherapy; however, most patients eventually 
die of recurrent disease ( Jett et al 2013 ). Estimated deaths from this disease are approximately 4% of all 
cancer mortality ( Jemal et al 2011 ). Median survival for patients treated with chemotherapy is 
approximately 12.7-12.9 months for limited-stage and 7.3 months for extensive-stage disease ( Powell et 
al 2014, Jhun et al 2013 ). In 2018, a phase 3 trial (Impower133) reported an improvement in median 
overall survival when anti-PD-L1 antibody, atezolizumab was used in combination with chemotherapy 
compared to chemotherapy alone (12.3 months vs. 10.3 months, p=0.0007) for the first-line treatment of 
extensive-stage SCLC ( Horn et al 2018 ). At the time of data cutoff at median follow-up of 13.9 months, 
94% patients had progressed or died in the chemotherapy alone arm. Addition of atezolizumab improved 
this number to only 85% demonstrating that majority of patients with extensive-stage SCLC eventually 
progress.  
 
One reason for the poor prognosis is due to limited treatment options for patients with recurrent disease. 
Recommended systemic therapy agents for patients with recurrent SCLC include topotecan, irinotecan, 
etoposide and gemcitabine ( Jett et al 2013 ). However, the response rates with these regimens are less 
than 10% to 15% with median PFS of less than 3 months. Recently, nivolumab with or without 
ipilumumab has been added to the NCCN guidelines as an option for recurrent disease. Nivolumab is an 
antibody that targets PD-1 and ipilumumab is an antibody targeting CTLA4, two immune checkpoints 
crucial for tumor growth. These recommendations are based on a phase 1/2 trial which reported response 
rate of 10% with nivolumab alone and 19% to 23% with the combination. Overall frequency of grade 3 
or 4 adverse events (AEs) was about 20% and the median PFS was 2.6 months with the combination 
(Antonia et al 2016 ). 
Plinabulin (BPI-2358), a synthetic analogue of the chemical halimide isolated from a marine fungus, is a 
vascular disrupting agent with pleomorphic immune effects, notably promoting the maturation of 
dendritic cells. Plinabulin induces tumor regression alone and synergistically with other standard 
chemotherapeutic agents in tumor models ( Bertelsen et al 2011) . Plinabulin has immune-enhancing 
effects through stimulation of dendritic cells, and antigen-specific CD4 T cell proliferation. In addition, 
plinabulin has pro-apoptotic effects on tumor cells, and reduces tumor blood flow. In preclinical models, 
the addition of plinabulin to PD1-inhibitors and CTLA4-inhibitors inhibits tumor growth approximately 
two-fold more than the PD1/CTLA4-inhibitor combination. Plinabulin also has anti-inflammatory 
effects through phosphodiesterase type 4 (PDE4)-inhibition, which may reduce immune-related AEs 
(irAEs), since PDE4 is a proven target for inflammation. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 13 of 77 In a phase 1 first-in-human trial in 38 patients, plinabulin (at the RP2D of 30 mg/m²), showed a 
favorable safety profile, while eliciting biological effects as evidenced by decreases in tumor blood flow, 
tumor pain, and other mechanistically relevant AEs ( Mita et al 2010 ). Findings from a phase 2 trial 
investigating the combination of plinabulin and docetaxel compared to docetaxel alone in patients with 
advanced non-small cell lung cancer (NSCLC) was presented at the ASCO-SITC Clinical Symposium in 
February, 2017 ( Mohanlal et al 2017 ). In addition to a trend towards a survival benefit in 76 patients 
with measurable disease (11.3 vs 6.7 months), plinabulin also protected against the development of 
docetaxel-induced AEs, especially neutropenia. The rate of grade 4 neutropenia was only 3% to 5% in 
the combination arm compared to 33% in the docetaxel alone arm (p <0.0003). Based on these findings, 
the global phase 3 DUBLIN-3 trial has been initiated to evaluate second- or third-line treatment with 
docetaxel plus plinabulin versus docetaxel in patients with advanced NSCLC. 
This study investigates the hypothesis that combining plinabulin with double checkpoint inhibition with 
anti-PD1 and anti-CTLA4 antibodies (nivolumab and ipilimumab respectively) will improve PFS as 
well as prevent irAEs, in patients with recurrent SCLC.  
1.2 Plinabulin (BPI-2358, previously known as NPI-2358) 
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by 
Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the 
diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-[[5-(1,1-
dimethylethyl)-1H-imidazol-4-yl[methylene]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-
dehydrophenylahistin). 
Plinabulin attacks cancer growth via several mechanisms. It inhibits angiogenesis, causes collapse of the 
existing tumor vasculature as well as directly inducing cancer cell apoptosis via the Ras-JNK pathway 
(Singh 2011). Furthermore, plinabulin enhances immune system function, inducing dendritic cell 
maturation, decreasing the regulatory T cell population and increasing the relative proportion of tumor-
killing CD8+ T cells and enhances CD4+ T-cell proliferation. Based on in vitro and in vivo nonclinical 
studies, plinabulin appears to have several advantages over other agents, namely; 1) multiple intrinsic 
anti-tumor actions, including a direct cytotoxic effect through the Ras-JNK pathway; 2) long-lasting 
(>24 hours) reduction in tumor blood flow; 3) anti-tumor effects against both small and large tumors; 4) 
enhancement of the tumor-relevant immune system function and 5) sustained inhibition on tumor 
growth after cessation of treatment. Thus, plinabulin could be an effective treatment for recurrent SCLC 
when administered in combination with anti-PD1 and anti-CTLA4 antibodies (nivolumab and 
ipilimumab, respectively). 
Plinabulin also exerts PDE4-inhibitory activity, which is associated with anti-inflammatory effects. 
PDE4-inhibitor drugs are approved to treat a number of inflammatory disorders, such as psoriasis, 
eczema, and chronic obstructive pulmonary disease. Thus Plinabulin has a unique profile, in that it is 
expected to exert immune-enhancing effects (through dendritic cell activation), while exerting anti-
inflammatory effects (through PDE4-inhibition). In addition, Plinabulin also has direct anti-cancer 
effects as outlined in the section below. 
1.2.1 Pharmacology 
Plinabulin exerts a marked inhibition of tubulin polymerization, resulting in shortening of newly formed 
tubulin polymer and disruption of the fine network of α-tubulin network in human umbilical vein 
endothelial cells (HuVECs, a model for tumor vascular endothelium) and tumor cells. In contrast to 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 14 of 77 vinca and taxane chemotherapeutics, plinabulin induces tubulin depolymerization without altering 
microtubule dynamics. This observation suggests that plinabulin could induce mitotic block with 
minimal disruption of other microtubule functions (e.g., axonal flow). In addition, plinabulin increases 
HuVEC permeability to high molecular weight molecules such as dextran, resulting in endothelial cell 
swelling, increasing vascular permeability and disruption of tumor blood flow. The combination of 
tumor vascular cell swelling which produces a hemorrhagic necrosis of the tumor, a direct cytotoxic 
effect on tumor cells through the Ras-JNK pathway, and inhibition of tumor angiogenesis results in a 
highly effective anti-tumor activity observed with this agent ( Nicholson 2006,  Singh 2011 ). Compounds 
which inhibit tubulin polymerization enhance immune function and synergize with immune checkpoint 
inhibitors in immune competent animal models ( Martin et al 2014 , Müller et al 2014 ). Plinabulin 
enhances immune system function as demonstrated by increased maturation of dendritic cells in vitro 
and by enhancing with immune checkpoint inhibitors and regulating T-cell function in vivo (Lloyd et al 
2016). 
Utilizing rodent models to assess tumor blood flow and tumor viability, plinabulin was shown to induce 
a highly selective and rapid vascular collapse and disruption of blood flow leading to central tumor 
necrosis without an observed effect on the vasculature in the surrounding fat pad or non-tumor tissues 
such as heart, lungs, and skeletal muscle. Alterations in tumor blood flow and morphology were 
associated with regression in tumor size. Plinabulin exerted potent cytotoxicity directly against tumor 
cell lines in vitro. The human HT-29 (colon), PC-3 (prostate), MDA-MB-231 (breast), RPMI-8226 
(multiple myeloma), and NCI-H292 (NSCLC) tumor cell lines were similarly sensitive with 
50% inhibitory concentrations (IC 50) ranging from 10 to 18 nM. This intrinsic cytotoxic effect was a 
result of mitotic block and the induction of apoptosis as evidenced by PARP cleavage, activation of 
caspase-3, -8, and -9 in multiple myeloma model. 
In vitro investigation in paclitaxel- or mitoxantrone-sensitive and resistant cell lines respectively, 
showed that the potency of plinabulin was not affected by the mechanisms for drug resistance to either 
paclitaxel (overexpression of P-glycoprotein) or mitoxantrone (decrease of topoisomerase II activity). 
Thus, it appears that the cytotoxicity of plinabulin on tumor cells was independent of common drug 
resistance mechanisms, suggesting its potential role in treating refractory or resistant diseases. 
In vivo tumor models in mice and rats demonstrated both single agent activity (e.g., against breast 
tumors, sarcomas, and multiple myeloma) and marked potentiation of common chemotherapeutics (e.g., 
against prostate, NSCLC, and colon carcinomas), and with radiation (in a mouse sarcoma model). 
Notably, plinabulin significantly enhanced the anti-tumor effect of docetaxel in a human NSCLC model 
of large tumors. The combination was observed to be better tolerated than docetaxel alone. In immune 
competent mice (MC-38 colon tumor model), plinabulin alone enhances immune system function and 
enhances the anti-tumor activity of immune checkpoint inhibitors. 
1.2.2 Pharmacokinetics and Drug Disposition 
The pharmacokinetics of plinabulin after intravenous (IV) administration was evaluated in the rat, dog, 
and monkey. The results of these studies demonstrated dose-dependency for AUC and C max. The 
elimination half-life (t ½) was dose-independent. The t ½ for plinabulin ranged from 1 to 2 hours in these 
species. 
In vitro microsome assays were performed to investigate metabolism of plinabulin. There was very little 
degradation of plinabulin observed over a 2-hour incubation period in human, dog, monkey, and rodent 
liver microsomes with or without metabolic activation. No metabolites of plinabulin have been 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 15 of 77 identified. Furthermore, plinabulin was a weak CYP inhibitor. It was not known whether plinabulin was 
a CYP substrate. The disappearance of plinabulin in vitro using human liver microsomes indicates slight 
metabolism that may be P450-mediated (mean 93% plinabulin remaining). The metabolic pathway has 
not yet been determined. When plinabulin was evaluated for P450 CYP inhibition in human liver 
enzymes, the mean (of 2 studies) percent inhibitions were 37% for CYP1A2, 60% for CYP2C9, 15% for 
CYP2C19, 17% for CYP2D6, and 12% for CYP3A4, at a concentration of 10 μM plinabulin, which was 
unlikely to be attained in humans clinically. Drug-drug interaction with commonly used medication was 
deemed unlikely. 
Plinabulin was 95% bound to human plasma proteins. In a mass distribution study in rats with 14C-
plinabulin, quantitative whole body autoradioluminography showed that the radioactivity distributed 
rapidly with the highest concentrations located in the wall of the small intestine, liver, kidney, and 
adrenals. Central nervous system (CNS), eye and bone exhibited C max below blood levels. The 
administered dose was excreted mainly via the urine, with contribution from fecal elimination. A total of 
7 metabolites were detected in plasma, urine, and feces. The major metabolite was similar in blood and 
urine, but different in feces. The metabolites have not been characterized. 
1.2.3 Toxicology and Safety Pharmacology 
The toxicology for plinabulin was studied in rats, dogs and monkeys. In the initial series of studies, the 
high concentration of organic solvent used in drug preparation for these studies contributed to the 
observed toxicology findings. These studies included the GLP IND-enabling toxicology study in dogs. 
After the toxic effect of solvent in vehicle was discovered, subsequent toxicology studies employed 
preparations with lower solvent concentration to test the plinabulin-specific toxicity. In the cardiac 
safety studies in the monkey, the vehicle used was closely approaching that used in clinical studies, and 
was without effect except for a slight (4-5%) transient reduction in heart rate. In the pivotal GLP toxicity 
study in the monkey, on the last day of dosing (but not on Day 1 or after the recovery period) minimal 
cardiac (44% increase in R-R and 10% increase in Q-T intervals without apparent change in the QTc 
interval) and cardiovascular (18% decrease in heart rate) effects were observed in the animals receiving 
42 mg/m2. 
From the GLP pivotal toxicity study in rats and monkeys (3 months, ICH S9 guidelines), GLP 
Investigational New Drug (IND)-enabling toxicology studies in the rat and dog, the echocardiography 
studies in dogs and monkeys, and from the reports of studies with other agents having the similar 
mechanism of action, the following are potential target organs for plinabulin: 
 Cardiovascular: Cardiovascular effects and cardiotoxicity have been reported for compounds that 
stabilize microtubule polymerization and reduce tumor blood flow. Cardiotoxicity was observed in 
toxicity studies for plinabulin in the rat and dog but not in nonhuman primates, even at very high 
doses. 
 Gastrointestinal tract 
 Nervous system 
 Bone marrow 
 Liver 
 Kidney 
 Injection site 
 Reproductive organs 
 Allergic reactions 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 16 of 77 These findings were generally reversible at all doses, including those characterized as severely toxic, 
except for the decreased body weight/food consumption, cardiac fibrosis, and testicular changes. It is 
worth pointing out that the above safety findings were made in studies using vehicle containing high 
concentration of organic solvent. The organic solvent used in vehicle for drug preparation in the clinical 
study would be 20-to 200-fold lower than it was in the above animal studies, potentially providing an 
additional margin of safety. 
1.2.4 Previous Clinical Experience with Plinabulin 
Two clinical studies with plinabulin have been conducted to date, a Phase 1 monotherapy study and a 
Phase 1/2 combination study with docetaxel in NSCLC. A total of 141 patients with advanced cancer 
received plinabulin. 
Study NPI-2358-100 was a Phase 1, open-label, dose-escalation study to determine the maximum-
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of plinabulin monotherapy in patients 
with advanced malignancies whose disease had progressed after treatment with standard treatments. 
Plinabulin was administered once per week (2 to 30 mg/m2) as an IV infusion for 3 successive weeks in 
repeating 4-week cycles. A total of 38 patients received plinabulin monotherapy ( Mita 2010 ). 
Pharmacokinetic analysis demonstrated a linear increase in C max and AUC with dose. The t ½ was 
approximately 6 hours. Pharmacodynamics was evaluated utilizing dynamic contrast-enhanced MRI 
which demonstrated decreases in K trans (a marker for tumor blood flow) at doses above 13.5 mg/m2. The 
decrease of tumor blood flow was dose dependent, with the greatest tumor flow decrease of 82% at 30 
mg/m2. 
Plinabulin was generally well tolerated. AEs occurring in ≥20% of patients included nausea (61%), 
vomiting (47%), diarrhea and fatigue (34% respectively), constipation, pyrexia, and headache (26% 
respectively), anorexia (24%), and anemia (21%). Overall, 16 patients (42%) experienced serious 
adverse events (SAEs), the majority were considered not related to plinabulin. The RP2D was 
determined to be 30 mg/m2. While no patient achieved a CR or PR, the proportion of patients with stable 
disease appeared to have increased with increasing plinabulin doses. A total of 7 (47%) out of 18 
evaluable patients achieved stable disease at the RP2D level (30 mg/m2). 
Study NPI-2358-101 was a Phase 1/2, open-label study to evaluate plinabulin in combination with 
docetaxel in patients with advanced NSCLC that had progressed after treatment with at least 
1 chemotherapy regimen. Study medication was administered by IV infusion on Day 1 (docetaxel and 
plinabulin) and Day 8 (plinabulin) of each 3-week cycle. The Phase 1 portion of the study investigated 
the safety of plinabulin/docetaxel (DN) combination with docetaxel dose fixed at the standard 75 mg/m2 
for NSCLC. Thirteen patients were enrolled sequentially in cohorts of plinabulin escalating from 
13.5 mg/m2 to 30 mg/m2. The RP2D of plinabulin was determined to be 30 mg/m2. The Phase 2 portion 
of the study explored the plinabulin effect on efficacy by comparing DN combination to docetaxel (D) 
alone. Patients were randomized to receive either docetaxel (75 mg/m2) in combination with plinabulin 
(30 mg/m2 or 20 mg/m2) or docetaxel (75 mg/m2) alone. A total of 90 patients (50 received plinabulin 30 
mg/m2, and 40 20 mg/m2, respectively) were randomized to the DN arm versus 73 patients to D arm. For 
the 30 mg/m2 Cohort, based on the intent-to-treat (ITT) analysis, the median overall survival (OS) was 
8.7 months in DN, and 7.5 months in D arm. The Hazard ratio (HR) was 0.97 with a p-value of 0.89. 
The objective response (OR) rate was 14.0% for DN and 14.5% for D; however, the median duration of 
response (DoR; which is a marker of immune enhancing activity), in patients receiving DN was 12.7 
months compared to the median of 1.5 months in patients receiving D alone. The improvement of DoR 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 17 of 77 was statistically significant (p=0.049) ( Millward et al 2012 ). A comparable improvement in DoR was 
observed with the 20 mg/m plinabulin dose. For the subgroup of patients with a measurable lung lesion 
(RECIST 1.1), the DN arm (n=38) had an mOS benefit of 4.6 months longer vs D alone (n=38), with the 
30 mg/m2 plinabulin dose ( Mohanlal et al 2017 ). 
Plinabulin was found to be generally well tolerated in combination with docetaxel. The combination 
appeared to have a similar AE profile as single-agent docetaxel. In patients receiving DN at 30 mg/m2 of 
plinabulin (RP2D), the most common AEs regardless of causality were diarrhea (58%), fatigue (52%), 
nausea (48%), constipation (36%), vomiting (34%), anorexia (34%), and hypertension (32%). The 
increase in gastrointestinal (GI)-related AEs is consistent with PDE4-inhibition, which is known to 
increase frequency of nausea, vomiting and diarrhea.  In addition a dose-dependent increase in ‘steroid’-
related AEs was observed, which is also suggestive of PDE4-inhibition with plinabulin. Unexpectedly, a 
significantly lower rate of neutropenia (all events and events ≥ grade 3) was observed in patients in DN 
arm than in D arm (p≤0.01). The use of granulocyte-colony stimulating factor and the rate of docetaxel 
dose reduction were also lower in DN than in D arm. 
Although there was no difference in the median duration of overall survival on the DN and D arms 
based on the ITT analysis, a post hoc exploratory analysis identified a subset (described below) of 
patients who appeared to benefit from treatment with plinabulin. 
1.3 Nivolumab 
Nivolumab is a fully human anti-PD-1 IgG4 monoclonal antibody. The PD-1/PD-L1 pathway is a 
crucial self-tolerance pathway that tumor cells hijack to escape immune elimination. The PD-1/PD-L1 
interaction inhibits T-cell response, induces apoptosis of tumor-specific T cells, and promotes 
differentiation of CD4 T cells into Tregs and tumor cell resistance ( Aerts et al 2013 ). PD-1 is expressed 
on the surface of activated T cells, B cells, and natural killer cells ( Agata et al 1996 ). Nivolumab has 
demonstrated durable responses exceeding 6 months as monotherapy and in combination with 
ipilimumab in several tumor types, including NSCLC, melanoma, renal cell carcinoma, classical 
Hodgkin Lymphoma, SCLC, gastric cancer, urothelial cancer, hepatocellular carcinoma, and colorectal 
cancer. Nivolumab is approved for use in multiple countries including the United States. Warnings for 
nivolumab include immune-mediated reactions, including pneumonitis, colitis, hepatitis, 
endocrinopathies, nephritis, rash, and encephalitis, as well as infusion reactions and embryo-fetal 
toxicity. The most common adverse reactions (≥20%) in patients with melanoma were fatigue, rash, 
musculoskeletal pain, pruritus, diarrhea, and nausea as a single agent, and fatigue, rash, diarrhea, nausea, 
pyrexia, vomiting, and dyspnea when administered with ipilimumab. In metastatic non-small cell lung 
cancer (NSCLC), the most common adverse reactions (≥20%) were fatigue, musculoskeletal pain, 
decreased appetite, cough, and constipation (BMS 2016). 
The pharmacokinetics (PK) of nivolumab were studied in subjects over a dose range of 0.1 to 10 mg/kg 
administered as a single dose or as multiple doses of nivolumab every 2 or 3 weeks. Nivolumab 
clearance (CL) decreases over time, with a mean maximal reduction (% coefficient of variation [CV%]) 
from baseline values of approximately 24.5% (47.6%) resulting in a geometric mean steady state 
clearance (CLss) (CV%) of 8.2 mL/h (53.9%); the decrease in CLss is not considered clinically relevant. 
The geometric mean volume of distribution at steady state (Vss) was 6.8 L (27.3%), and geometric mean 
elimination half-life (t 1/2) was 25 days (77.5%). Steady-state concentrations of nivolumab were reached 
by 12 weeks when administered at 3 mg/kg q2w, and systemic accumulation was approximately 3.7-
fold. The exposure to nivolumab increased dose proportionally over the dose range of 0.1 to 10 mg/kg 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 18 of 77 administered every 2 weeks. Additionally, nivolumab has a low potential for drug-drug interactions. The 
clearance of nivolumab increased with increasing body weight. The population PK (PPK) analysis 
suggested that the following factors had no clinically important effect on the CL of nivolumab: age (29 
to 87 years), gender, race, baseline LDH, PD-L1, solid tumor type, baseline tumor size, and hepatic 
impairment.  
1.4 Ipilimumab 
Ipilimumab is a fully humanized monoclonal antibody (mAb) against the CTLA-4 epitope that 
neutralizes the receptor, thus enabling cytotoxic T cell activity and perpetuating immune responses. 
Most of the benefits of anti CTLA- 4 blockade seem to be mediated by depletion of T-regulatory (Treg) 
cells as these cells demonstrate high levels of CTLA-4 expression ( Peggs et al 2009 ). Ipilimumab is 
being investigated both as monotherapy and in combination with other modalities such as chemotherapy, 
radiation therapy, and other immunotherapies. Ipilimumab is approved for the treatment of melanoma in 
multiple countries. Warnings for ipilimumab include immune-mediated reactions, including hepatitis 
and endocrinopathies, as well as embryo-fetal toxicity. The most common adverse reactions (≥5%) have 
been fatigue, diarrhea, pruritus, rash, and colitis. At the 10 mg/kg dose (higher than anticipated in this 
study), additional common adverse reactions (≥5%) include nausea, vomiting, headache, weight loss, 
pyrexia, decreased appetite, and insomnia (BMS 2015). 
The PK of ipilimumab has been extensively studied in subjects with melanoma, at the 3- and 10-mg/kg 
doses administered as a 1.5-hour IV infusion. The PK of ipilimumab was characterized by PPK analysis 
and determined to be linear and time invariant in the dose range of 0.3 to 10 mg/kg. The summary of PK 
parameters after single and multiple doses of ipilimumab in subjects with advanced melanoma from 
Studies MDX010-15, CA184007, and CA184008 (with intensive PK samples available) are listed in 
Table 5.2.1-1 of the Ipilimumab IB. The PPK of ipilimumab was studied in 785 subjects (3200 serum 
concentrations) with advanced melanoma in 4 Phase 2 studies (CA184004, CA184007, CA184008, and 
CA184022), 1 Phase 3 study (CA184024), and 1 Phase 1 study (CA184078). The PPK analysis 
demonstrated that the PK of ipilimumab is linear, the exposures are dose proportional across the tested 
dose range of 0.3 to 10 mg/kg, and the model parameters are time-invariant, similar to that determined 
by noncompartmental analyses. Upon repeated dosing of ipilimumab, administered every 3 weeks 
(q3w), minimal systemic accumulation was observed by an accumulation index of 1.5-fold or less, and 
ipilimumab steady-state concentrations were achieved by the third dose. The ipilimumab CL of 16.8 
mL/h from PPK analysis is consistent with that determined by noncompartmental PK analysis and 
shown in Table 5.2.1-1 of the Ipilimumab IB. The terminal T1/2 and Vss of ipilimumab calculated from 
the model were 15.4 days and 7.47 L, respectively, which are consistent with that determined by 
noncompartmental analysis. Volume of central compartment (Vc) and peripheral compartment were 
found to be 4.35 and 3.28 L, respectively, suggesting that ipilimumab first distributes into plasma 
volume and, subsequently, into extracellular fluid space. CL of ipilimumab and Vc were found to 
increase with increase in body weight. However, there was no significant increase in exposure with 
increase in body weight when dosed on a milligram/kilogram basis, supporting dosing of ipilimumab 
based on a weight normalized regimen. The PK of ipilimumab is not affected by age, gender, race, and 
immunogenicity (anti-drug antibody [ADA] status); concomitant use of chemotherapy, prior therapy, 
body weight, performance status; or tumor type. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 19 of 77 1.5 Nivolumab and Ipilimumab Combination 
In CA209004, a Phase 1B dose-escalation study of nivolumab in combination with ipilimumab in 
subjects with unresectable stage III or IV malignant melanoma, the 3 mg/kg nivolumab and 3 mg/kg 
ipilimumab cohort exceeded the MTD per protocol. While both Cohort 2 (1 mg/kg nivolumab + 3 mg/kg 
ipilimumab) and Cohort 2a (3 mg/kg nivolumab + 1 mg/kg ipilimumab) had similar clinical activity, a 
dose of 3 mg/kg of ipilimumab q3w for a total of 4 doses and 1 mg/kg nivolumab q3w for 4 doses 
followed by nivolumab 3mg/kg every 2 weeks (q2w) until progression, was chosen. Exposure-response 
analysis of nivolumab monotherapy across dose ranges of 1 mg/kg to 10 mg/kg reveals similar clinical 
activity while exposure-response analysis of 0.3 mg/kg, 3 mg/kg, and 10 mg/kg of ipilimumab 
monotherapy have demonstrated increasing activity with increase in dose in the Phase 2 study 
CA184022 ( Wolchok et al 2009 ). Therefore, the selection of 3 mg/kg of ipilimumab (Cohort 2) may be 
more clinically impactful than selection of 3 mg/kg of nivolumab (Cohort 2a). Data from the Phase 3 
study CA209067 in subjects with advanced melanoma showed that the administration schedule of 1 
mg/kg of nivolumab q3w plus 3 mg/kg of ipilimumab q3w for 4 doses, followed by 3 mg/kg of 
nivolumab q2w for cycle 3 and beyond is safe and well tolerated ( Larkin et al 2015 ). Anti-CTLA4 
targeted therapy has been reported to be efficacious also in patients with resistance to prior anti-PD-
1/PD-L1 therapy in multiple retrospective studies ( Zimmer et al 2017 , Jacobsoone-Ulrich et al 2016 , 
Aya et al 2016 ). Multiple trials are now ongoing with PD-1/PD-L1 targeted therapy and ipilimumab to 
investigate the efficacy of this combination in patients with primary or secondary resistance to 
immunotherapy.  
In a Phase 1/2 study by Antonia et al, nivolumab with or without ipilimumab showed antitumor activity 
with durable responses and manageable safety profiles in previously treated patients with SCLC: 
nivolumab 3 mg/kg q2w achieved a PR and stable disease (SD) in 10% (10/98) and 22% (22/98), 
respectively, while the combination of nivolumab and ipilimumab (1 and 1 mg/kg, 1 and 3 mg/kg, or 3 
and 1 mg/kg, respectively) q3w x 4 followed by nivolumab 3 mg/kg q2w achieved an objective response 
rate (ORR) and SD in 23% (14/61) and 19% (10/54), respectively ( Antonia et al 2016 ). Treatment was 
generally well tolerated, with grade 3 or higher treatment-related AEs occurring in 13 (13%) patients in 
the nivolumab 3 mg/kg cohort, 18 (30%) in the nivolumab 1 mg/kg plus ipilimumab 3 mg/kg cohort, 
and 10 (19%) in the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg cohort; the most commonly reported 
grade 3 or 4 treatment-related AEs were increased lipase (none vs. 5 [8%] vs. none) and diarrhea (none 
vs. 3 [5%] vs. 1 [2%]). No patients in the nivolumab 1 mg/kg plus ipilimumab 1 mg/kg cohort had a 
grade 3 or 4 treatment-related AE. Six (6%) patients in the nivolumab 3 mg/kg group, 7 (11%) in the 
nivolumab 1 mg/kg plus ipilimumab 3 mg/kg group, and 4 (7%) patients in the nivolumab 3 mg/kg plus 
ipilimumab 1 mg/kg group discontinued treatment due to treatment-related AEs. Two patients who 
received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg died from treatment-related AEs (myasthenia 
gravis and worsening of renal failure), and 1 patient who received nivolumab 3 mg/kg plus ipilimumab 1 
mg/kg died from treatment-related pneumonitis. Nivolumab and the combination of nivolumab and 
ipilimumab, therefore, appear to have clinically significant therapeutic potential in SCLC ( Antonia et al 
2016).  
1.5.1 Rational for Nivolumab and Ipilimumab Dosing 
CheckMate 032 was a phase I/II trial that evaluated multiple regimens of nivolumab in combination 
with ipilimumab in solid tumors, including advanced SCLC. There were four initial treatment arms: 
patients with advanced SCLC and disease progression after prior platinum-based chemotherapy were 
assigned to nivolumab (3 mg/kg Q2W; n = 98), nivolumab 1 + ipilimumab 1 (n=3),  nivolumab 1 + 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 20 of 77 ipilimumab 3 (1 mg/kg and 3 mg/kg Q3W x 4, then nivolumab 3 Q2W; n = 61) and nivolumab 3 + 
ipilimumab 1 (n=54). Safety and efficacy was assessed with a follow-up of 18 months. The early results 
from the four initial treatment arms were reported by Antonia et al in 2016 as described above (Antonia 
et al 2016). Grade 3 or 4 treatment-related AEs occurred in 13% patients in the nivolumab 3 mg/kg 
cohort, 30% in the nivolumab 1 + ipilimumab 3 cohort, and 19% in the nivolumab 3 + ipilimumab 1 
cohort. Six percent of the patients in the nivolumab 3 mg/kg group, 11% in the nivolumab 1 + 
ipilimumab 3 group, and 7% in the nivolumab 3 + ipilimumab 1 group discontinued treatment due to 
treatment-related adverse events. Two patients who received nivolumab 1 + ipilimumab 3 mg/kg died 
from treatment-related AEs (myasthenia gravis and worsening of renal failure), and one patient who 
received nivolumab 3 + ipilimumab 1 died from treatment-related pneumonitis. Based on these results 
from the initial four treatment arms, it was determined to use nivolumab 1 + ipilimumab 3 for the 
subsequent expansion for this combination. For the expansion cohort, patients were randomized 3:2 to 
nivolumab vs nivolumab 1 + ipilimumab 3 and stratified by a number of prior therapies. A total of 247 
pts were randomized to the two arms. Preliminary results from the randomized expansion were reported 
by Hellmann et al at the annual ASCO meeting in Chicago in June 2017 (Hellmann MD, Ott PA, 
Zugazagoitia J, et al. First report of a randomized expansion cohort from CheckMate 032, J Clin Oncol 
2017;35: Abstract 8503). Of the 159 patients who were evaluable, 98 received nivolumab only and 61 
received nivolumab 1 + ipilimumab 3. The ORR was 11% in the nivolumab arm vs. 25% in the 
combination arm. The combination of nivolumab 1 + ipilimumab 3 was well tolerated with 33% of the 
patients experiencing grade 3-4 treatment related adverse event (vs. 14% in the nivolumab only arm) and 
11% discontinuing treatment due to adverse events. Based on the safety and efficacy date from initial 
results and follow-up expansion cohort from CheckMate 032, the combination of nivoumab 1 + 
Ipilimumab 3 has been included as a second-line (or beyond) option for the treatment of recurrent SCLC 
in the NCCN guidelines for SCLC. In our study, we will therefore use the nivolumab 1 + ipilimumab 3 
dosing regimen in combination with escalating dose cohorts of plinabulin. 
1.6 Nivolumab, Ipilimumab and Plinabulin Combination 
Plinabulin induces tumor regression alone and synergistically with other standard chemotherapeutic 
agents in tumor models ( Bertelsen et al 2011) . Plinabulin has immune-enhancing effects through 
stimulation of dendritic cells, and antigen-specific CD4 T cell proliferation. In addition, plinabulin has 
pro-apoptotic effects on tumor cells, and reduces tumor blood flow. In preclinical models, the addition 
of plinabulin to PD1-inhibitors and CTLA4-inhibitors inhibits tumor growth approximately two-fold 
more than the PD-1/CTLA4-inhibitor combination only. Therefore, in our study, we aim to test the 
hypothesis that the combination of PD-1 and CTLA-4 inhibition will be synergistic with plinabulin. 
Moreover, Plinabulin has anti-inflammatory effects through phosphodiesterase type 4 
(PDE4)-inhibition, which may reduce immune-related adverse events, since PDE4 is a proven target for 
inflammation. Therefore, we hypothesize that combination of plinabulin with PD-1/CTLA4 combination 
may result in fewer immune-related side effects leading to better tolerance and fewer treatment 
discontinuation of the immunotherapy regimen. The overall goal of this study is to investigate if 
combining plinabulin with double checkpoint inhibition with anti-PD1 and anti-CTLA4 antibodies 
(nivolumab and ipilimumab respectively) will improve PFS as well as prevent irAEs, in patients with 
recurrent SCLC. 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 21 of 77 2. STUDY OBJECTIVES AND ENDPOINTS 
2.1 Objectives 
This study will be conducted in two parts: a Phase I dose escalation part and a Phase II part. 
2.1.1 Primary Objective 
Phase I: 
 The primary objective of the Phase I dose escalation study is to establish the MTD of plinabulin 
in combination with nivolumab and ipilimumab for patients with recurrent SCLC. 
Phase II: 
 The primary objective of the Phase II, single arm study is to determine if the addition of 
plinabulin (at the 30 mg/m2 dose) to double checkpoint inhibition (PD-1 and CTLA-4) for 
recurrent SCLC will improve PFS (the time from treatment assignment to the date of the first 
documented tumor progression, or death due to any cause, whichever occurred first). 
2.1.2 Secondary Objectives 
The secondary objectives are: 
 To assess toxicity and tolerability of the combination of nivolumab, ipilimumab and plinabulin. 
 To measure the frequency of immune-related adverse events (irAEs). irAE’s are defined as any 
treatment-related AE that is inflammatory in nature, consistent with the mechanism of action of 
immunotherapy and generally medically manageable with topical and/or systemic 
immunosuppressants.  
 To determine the proportion of patients with a confirmed objective response in the 2 arms of the 
Phase II part (defined as the number of patients with a best overall response of complete 
response [CR] or PR divided by the number of assigned patients). 
 To estimate clinical benefit rate (CBR: complete response, partial response, or stable disease). 
 To estimate 6-month (±4 weeks) PFS. 
 To estimate overall survival (OS) and 1-year OS. 
2.1.3 Correlative/Exploratory Objectives 
 To measure biomarkers of inflammation (high sensitivity C-reactive protein [hsCRP], 
erythrocyte sedimentation rate [ESR], serum amyloid A [SAA]) and haptoglobin. 
 To correlate tumor mutational burden with PFS and ORR 
 To measure biomarkers of activity such as immune cell phenotypes, TCR-seq, and circulating 
cytokines and to correlate with PFS and ORR.  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 22 of 77 2.2 Endpoints 
2.2.1 Primary Endpoints 
 Phase I: Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for 
Adverse Events (NCI CTCAE) v4. 
 Phase II: PFS is defined as the time from D1 of treatment until the criteria for disease 
progression is met as defined by RECIST1.1 or death as a result of any cause.  
 
2.2.2 Secondary Endpoints 
 The objective response rate (ORR) is the proportion of all subjects with confirmed PR or CR 
according to RECIST 1.1, from the start of treatment until disease progression/recurrence. 
 Overall survival is defined by the date of registration to date of death from any cause. 
 Clinical Benefit Rate (CBR) is defined as the percentage of patients who achieve CR, PR and 
stable disease. 
 
3. ELIGIBILITY CRITERIA 
3.1 Inclusion Criteria 
The patients must satisfy all of the following inclusion/exclusion criteria in order to be eligible for the 
study: 
1. Must have signed and dated written informed consent form in accordance with regulatory and 
institutional guidelines. 
2. Males and females aged >18 years at time of consent. 
3. Histological or cytological confirmed extensive-stage SCLC  
4. Patients who progressed after at least 1 platinum-based chemotherapy regimen. Patients with 
platinum resistance (defined as recurrence or progression of disease within 90 days of 
completion of the platinum-based regimen) are eligible. For phase II, patients also must have 
been treated with at least one prior line of PD-1/PD-L1 therapy. 
5. Measurable disease according to RECIST v1.1 (Section 8) obtained by imaging within 28 days 
prior to study registration. 
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days 
before registration and minimum life expectancy of at least 12 weeks. 
7. Treatment to be initiated at least 2 weeks since last dose of prior systemic anticancer therapy 
(chemotherapy, radiation, and/or surgery.  
8. Recovery to grade 1 of any clinically significant toxicity (excluding alopecia, grade 2 fatigue, 
vitiligo, endocrinopathies on stable replacement therapy) prior to initiation of study drugs. 
9. Female patients of childbearing potential have a negative pregnancy test at baseline. Females of 
childbearing potential are defined as sexually mature women without prior hysterectomy or who 
have had any evidence of menses in the past 12 months. However, women who have been 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 23 of 77 amenorrheic for 12 or more months are still considered to be of childbearing potential if the 
amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression. 
a. Women of childbearing potential (i.e., menstruating women) must have a negative urine 
pregnancy test (positive urine tests are to be confirmed by serum test) documented within 14 
days of study registration and within the 24-hour period prior to the first dose of study drug.  
b. Sexually active women of childbearing potential enrolled in the study must agree to use 2 
forms of accepted methods of contraception during the course of the study and for 23 weeks 
after their last dose of study drug. Effective birth control includes (a) intrauterine device plus 
1 barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., 
oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. 
Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams 
or gels that contain a chemical to kill sperm); or (d) a vasectomized partner. 
c. For male patients who are sexually active and who are partners of premenopausal women: 
agreement to use 2 forms of contraception as in criterion 9b above during the treatment 
period and for 31 weeks after the last dose of study drug. 
10. Adequate laboratory values. 
a. Absolute neutrophil count ≥1,000/µL 
b. Platelet count ≥100,000/µL 
c. Hemoglobin ≥9.0 g/dL 
d. Total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for subjects with Gilbert’s 
disease 
e. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN (≤5 x 
ULN if evidence of hepatic involvement by malignant disease) 
f. Creatinine ≤ 1.5 x ULN or estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2 
g. Lipase and Amylase ≤1.5 x ULN. Subjects with Lipase >1.5 x ULN may enroll if there are 
neither clinical nor radiographic signs of a pancreatitis. 
3.2 Exclusion Criteria 
Patients with any of the following will be excluded from participation in the study. 
1. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring 
treatment with steroids. Prior history of radiation pneumonitis is allowed if pneumonitis was 
restricted to the field of radiation. 
2. History of ileus or other significant gastrointestinal disorder known to increase the risk of ileus 
or chronic bowel hypomotility 
3. Pregnant or breastfeeding, or expecting to conceive or father children within the projected 
duration of the trial, starting with the pre-screening or screening visit through 23 weeks (female) 
or 31 weeks (male) after the last dose of study drug. 
4. Must not have received CTLA-4 targeted therapy previously 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 24 of 77 5. Treatment with any investigational agent within 28 days prior to registration for protocol 
therapy. Vaccination for SARS-CoV-2 is allowed as well as any therapy as required for the 
treatment of active COVID 19 infection.  
6. Known active symptomatic central nervous system (CNS) metastases and/or carcinomatous 
meningitis. Patients with neurological symptoms must undergo a head computed tomography 
(CT) scan or brain magnetic resonance imaging (MRI) to exclude brain metastasis. Patients 
whose brain metastases have been treated may participate provided there is no evidence of 
progression for at least 2 weeks after CNS-directed treatment, as ascertained by clinical 
examination or brain imaging.  
7. Known history of human immunodeficiency virus (HIV) or active hepatitis B (by surface antigen 
expression or polymerase chain reaction [PCR]) or active hepatitis C (by PCR) infection. NOTE: 
HIV testing is not required; Hepatitis B and C testing are required at screening. 
8. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of 
immunosuppressive therapy within 7 days prior to study registration. 
9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with 
use of disease modifying agents, corticosteroids, or immunosuppressive drugs) or a documented 
history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or 
immunosuppressive agents. Vitiligo, alopecia, hypothyroidism only requiring hormone 
replacement, psoriasis not requiring systemic treatment, celiac disease controlled by diet alone or 
conditions not expected to recur in the absence of an external trigger are permitted. 
10. A condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone 
equivalent) or other immunosuppressive medications within 14 days prior to administration of 
study drugs. 
11. History of psychiatric illness or social situations that would limit compliance with study 
requirements.  Has a history or current evidence of any condition, therapy, or laboratory 
abnormality that might confound the results of the trial, interfere with the patient’s participation 
for the full duration of the trial, or is not in the best interest of the patient to participate, in the 
opinion of the treating investigator.  
12. Prior malignancies (except non-melanoma skin cancers, and the following in situ cancers: 
bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete 
remission was achieved at least 2 years prior to study entry.  
13. Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable 
angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association 
(NYHA) Class III–IV within 6 months prior to their first dose of study drugs. 
14. Evidence of ongoing inadequately controlled hypertension (defined as baseline systolic blood 
pressure >160 mmHg or diastolic blood pressure >100 mmHg). 
15. Any active grade 3 or higher viral, bacterial, or fungal infection within 2 weeks of the first dose 
of the study drugs. Routine antimicrobial prophylaxis is permitted. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 25 of 77 4. SUBJECT REGISTRATION 
All subjects must be registered through Big Ten Cancer Research Consortium (Big Ten CRC) 
Administrative Headquarters’(AHQ) electronic data capture (EDC) system. A subject is considered 
registered when an ‘On Study’ date is entered into the EDC system. 
 
Subjects must be registered prior to starting protocol therapy. Subjects must begin therapy within 5 
business days  of registration.  
5. STUDY DESIGN 
5.1 Overview of Study Design 
This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase 
II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and 
who are candidates for second-line therapy.  
No PK evaluation is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin’s 
PK, since the route of excretion is different. 
5.2 Phase I (Dose Escalation) 
The primary objective of the Phase I part of the study is to define the MTD of the triple combination of 
nivolumab, ipilimumab and plinabulin.  
Dosing Regimen: 
On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) 
and plinabulin (escalating cohorts, IV).  
After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with 
nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment 
criteria occur. 
Dose Escalation: 
Dose escalation will follow a standard 3+3 design (Table 1). Patients will enter into cohorts of at least 3 
evaluable patients starting with the initial plinabulin dose level at 20 mg/m2 (Dose Level 1). If Dose 
Level 1 is deemed tolerable, the next cohort of patients will be enrolled into Dose Level 2 (plinabulin at 
30 mg/m2).  
Table 1 Dose Escalation Schedule 
Dose Level Nivolumab  
Day 1 of each cycle Ipilimumab  
Day 1 of each cycle Plinabulin 
Day 1 of each cycle 
Level -1 1 mg/kg 3 mg/kg 13.5 mg/m2 
Level 1 (start) 1 mg/kg 3 mg/kg 20 mg/m2 
Level 2 1 mg/kg 3 mg/kg 30 mg/m2 
In addition to the above dose levels, there are also 1 level below the initial level, in case the initial level 
has unacceptable toxicity.  
The MTD is defined as the dose level at which fewer than 33% of subjects experience a dose limiting 
toxicity (DLT), and specifically is the dose level at which less than 2 out of 6 subjects experience DLT. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 26 of 77 As no dose escalation is planned beyond level +2, if less than 2 out of 6 subjects experience DLT at 
level +2, MTD will be determined at this level (with no requirement for DLT at next higher dose level). 
The MTD will be the recommended dose for the Phase II component of the study. 
 
Subjects will initially be enrolled onto dose level 1. Three to six evaluable subjects will be enrolled at 
each dose level. All subjects assigned to a dose level must be followed for at least 42 days (2 cycles) 
before dose escalation to the next cohort level can begin. 
 
Note: Subjects not evaluable for DLT assessment (i.e. do not complete at least 2 cycles of therapy due to 
reasons other than toxicity) on the Phase I portion of the protocol will be replaced for determination of 
dose escalation. 
 
The following rules will be followed: 
 
 An initial three subjects will be enrolled at dose level +1. If all 3 subjects in dose level +1 complete 
4 weeks of therapy without dose limiting toxicity (DLT), the study will proceed to enroll 3 subjects 
at dose level +2. If all 3 subjects in dose level +2 complete 2 cycles of therapy without DLT, 3 more 
subjects will be enrolled to ensure that only 0-1 of 6 subjects have a DLT and then proceed to the 
Phase II cohort. As dose level +2 represents the recommended phase II dose of plinabulin in single 
agent studies, there will be no further dose escalation beyond dose level +2. 
 
 Alternatively, if 1 of the first 3 subjects in any given dose cohort experiences DLT, an additional 3 
subjects will be enrolled at that dose level. If only 1 of the total 6 subjects in a dose level experience 
DLT, the study will proceed to the next dose level as planned. If 2 of the total 6 subjects in any given 
dose cohort experience DLT, the next lower dose level will be explored and considered the 
maximum tolerated dose (MTD) if no more than 1 of 6 subjects experience a DLT. That dose will be 
recommended for the Phase II study. 
 
 If 2 or more DLTs are reached in dose level -1, the study will be put on hold and a protocol amendment 
will be considered. 
 
Dose Escalation Rules 
 
Number of subjects with 
DLT at given dose level Escalation decision 
0 out of 3 Enter 3 subjects at the next dose level. 
≥2 out of 3 Dose escalation will be stopped. This dose level will be declared 
the maximum administered dose . Three (3) additional subjects 
will be entered at the next lower dose level if only 3 subjects 
were treated previously at that next lower dose level. 
1 out of 3 Enter at least 3 more subjects at this dose level: 
 If 0 of these additional 3 subjects experience DLT, proceed to 
the next dose level. 
 If 1 or more of these additional 3 subjects experience DLT, 
then dose escalation is stopped and this dose is declared the 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 27 of 77 maximum administered dose. Three (3) additional subjects 
will be entered at the next lower dose level if only 3 subjects 
were treated previously at that dose.  
≤1 out of 6 at highest dose 
level below the maximum 
administered dose This will be defined as the MTD. This dose level will be the 
recommended Phase II dose.  
 
5.3 Definition of Dose-Limiting Toxicity 
Dose-limiting toxicities (DLTs) will be assessed for each patient within 42 days of first plinabulin dose. 
Any suspected or confirmed DLT should be reported immediately (within 1 business day) to Big Ten 
CRC Administrative Headquarters.  
DLTs will be counted based on the number of subjects with DLT at a given dose level, not the absolute 
number of DLTs. No single subject can trigger more than one DLT event. 
 
Intra-subject dose escalation is not permitted. 
A DLT is defined as any of the following treatment-related AEs or laboratory abnormalities, graded 
according to NCI CTCAE version 4: 
 Febrile neutropenia 
 Grade 4 hypertension 
 Grade 4 anemia unrelated to underlying disease 
 Grade 3 thrombocytopenia with clinically significant bleeding or grade 4 thrombocytopenia 
lasting more than 7 days and/or requiring a platelet transfusion 
 Grade 4 neutropenia lasting more than 7 days 
 ≥Grade 3 nausea, vomiting, diarrhea, or electrolyte imbalances lasting >48 hours despite optimal 
prophylactic and curative treatment 
 ≥Grade 3 hypersensitivity reaction (unless first occurrence and resolves within 6 hours with 
appropriate clinical management) 
 Treatment delay >21 days secondary to recovery from study drugs-related AEs.  
 ≥Grade 3 non-hematologic AEs, except for the exclusions listed below. 
 Any toxicity requiring permanent discontinuation of treatment, including: 
o Grade ≥3 diarrhea 
o Grade ≥3 adrenal insufficiency 
o Grade 4 hyperglycemia 
 
The following events will be excluded from the DLT definition: 
 Any AE ≥grade 3 clearly determined to be unrelated to study drug(s) (e.g., disease progression) 
 ≥Grade 3 isolated alkaline phosphatase laboratory abnormality of any duration 
 ≥Grade 3 isolated, asymptomatic amylase or lipase laboratory abnormality of any duration 
 ≥Grade 3 endocrinopathies controlled by corticosteroids or hormone replacement 
 Vitiligo or Alopecia of any grade 
 Grade 3 fatigue. 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 28 of 77 In order to be evaluable for DLT assessment, patients must receive a complete dose of nivolumab, 
ipilimumab and plinabulin. Patients who experience a DLT within the first 42 days of treatment and 
drop out of the study will be considered evaluable for DLT and will not be replaced. Patients who drop 
out of the study for reasons other than DLT will be considered not evaluable and will be replaced.  
5.4 Phase II  
The primary objective of the Phase II part of the study is to determine if the addition of plinabulin to 
double checkpoint inhibition (PD-1 and CTLA-4) for recurrent SCLC will improve PFS. Phase II will 
begin after the R2PD of plinabulin is identified for use in combination with nivolumab and ipilimumab. 
The RP2D of plinabulin is 30 mg/m2. 
 
6. TREATMENT PLAN 
Study treatment will be administered as 21-day cycles for the first 4 cycles and as 14-day cycles during 
the maintenance period.  
For patients with a body surface area (BSA) greater than 2.4 m2, dosing should be calculated using a 
maximum BSA of 2.4 m2 for plinabulin. 
6.1 Phase I (Dose Escalation) 
6.1.1 Cycles 1 to 4 (cycle = 21 days) 
Patients will be treated in cohorts of at least 3 patients.  On Day 1 of each 21-day cycle, all patients will 
receive treatment with: 
 First: Nivolumab 1 mg/kg administered via IV infusion over 30 minutes (-5/+10 minutes)  
 Second: Ipilimumab 3 mg/kg administered via IV infusion over 30 minutes (-5/+10 minutes) 
 Third: Plinabulin administered via IV infusion over 60 minutes (-5/+10 minutes) beginning 
1 hour (± 10 minutes) after the end of the ipilimumab infusion.  
6.1.2 Cycle 5 and Subsequent Cycles (Maintenance) (cycle = 14 days) 
After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with 
nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment 
criteria occur. 
On Day 1 of each 14-day cycle, all patients will receive treatment with: 
 First: Nivolumab 240 mg administered via IV infusion over 30 minutes (-5/+10 minutes) 
 Second: Plinabulin administered via IV infusion over 60 minutes (-5/+10 minutes) beginning 30 
minutes (± 5 minutes) after the end of the nivolumab infusion.  
6.2 Phase II  
Up to 26 patients will enrolled to receive the triple combination of plinabulin + nivolumab + 
ipilimumab. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 29 of 77 6.2.1 Cycles 1 to 4 (cycle = 21 days) 
Patients will receive study treatment via IV infusion on Day 1 in a 21-day cycle:  
 First: Nivolumab 1 mg/kg administered via IV infusion over 30 minutes(-5/+10 minutes) 
 Second: Ipilimumab 3 mg/kg administered via IV infusion over 30 minutes(-5/+10 minutes) 
 Third: Plinabulin at RP2D administered via IV infusion over 90 minutes (-5/+10 minutes) 
beginning 1 hour (± 10 minutes) after the end of the ipilimumab infusion. Plinabulin can be 
administered over 60 minutes cycle 3 onwards if patient does not experience an infusion 
reaction with the first two cycles.  
6.2.2 Cycle 5 and Subsequent Cycles (Maintenance) (cycle = 14 days) 
After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with 
nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment 
criteria occur. 
On Day 1 of each 14-day cycle, patients will receive treatment with: 
 First: Nivolumab 240 mg administered via IV infusion over 30 minutes (-5/+10 minutes) 
 Second: Plinabulin administered via IV infusion over 60 minutes (-5/+10 minutes) beginning 30 
minutes (± 5 minutes) after the end of the nivolumab infusion.  
6.3 Vital Signs During Plinabulin Infusions 
Vital signs (temperature, blood pressure, heart rate, and respiratory rate) should be measured 
immediately before and after (±10 min) plinabulin infusions, and 30 and 60 minutes following (±10 
minutes) plinabulin infusion during Cycle 1 Day 1. Thereafter, vital signs will be collected immediately 
before and after each infusion (±10 min). Abnormal vital signs (especially hypertension) should be 
followed until resolution to ≤ Grade 1 or baseline and/or deemed clinically insignificant, whichever 
occurs first. 
6.4 Allowed Concomitant Medications 
If an increase in systolic blood pressure to >160 mmHg is observed after administration of plinabulin, 
oral amlodipine 10 mg or an equivalent calcium channel blocker should be administered before each 
subsequent dose. Increases in systolic blood pressure above 200 mmHg should be managed with 
nitroprusside or similar regimen per institutional practice. If hypertension can be successfully managed, 
the patient can continue in the study at the discretion of the treating Investigator.  
 
The Investigator should be experienced in the use of nivolumab and ipilumumab and familiar with the 
prescribing information provided by the manufacturer. According to the prescribing information, there 
have been no formal clinical studies to evaluate the drug interactions of either nivolumab or ipilumumab 
with other medications. 
 
Any other medication which is considered necessary for the patient’s welfare, including 
bisphosphonates, and which is not expected to interfere with the evaluation of the study drug, may be 
given at the discretion of the Investigator. Vaccination for SARS-CoV-2 as well as any therapy as 
required for the treatment for active COVID 19 infection is allowed. However, vaccination is not 
recommended on the day of IP administration. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 30 of 77  
All medications will be recorded in an appropriate section of the CRF. 
 
No other cancer therapies or investigational agents are permitted during the entire duration of the study 
treatment (from 14 days before the first administration until the 30-day safety evaluation). 
6.5 Supportive Care 
Plinabulin is associated with the occurrence of nausea, vomiting and diarrhea. These GI-related AEs are 
dose-dependent and occur primarily at the 30 mg/m2 plinabulin dose, and if infused over 30 minutes.  
With infusion time of 60 minutes, the frequency of these GI-related AEs is markedly reduced. A 60-
minute infusion time is implemented in this protocol. Nevertheless, if GI-related AEs occur after the 
first plinabulin dosing, consider administering anti-emetic prophylaxis with subsequent plinabulin 
dosing. 
 
Appropriate anti-emetic prophylaxis (excluding steroids) should be given per institutional policy prior to 
plinabulin infusion to prevent nausea or vomiting. Suggested regimen includes a 5HT3 antagonist such 
as palonosetron. The use of anti-emetics must be recorded on the eCRF. 
 
If diarrhea occurs, it must be treated. Anti-diarrheals such as loperamide (or diphenoxylate/atropine) 
must be prescribed for diarrhea. Suggested loperamide use: 4 mg orally after first loose stool, then 2 mg 
after each stool not to exceed 16 mg in 24 hours. Anti-diarrheal medications must be recorded on the 
eCRF.  
 
Milk and milk products should be avoided, and other appropriate dietary interventions should be advised 
to patients. Patients should also be cautioned to avoid dehydration, and of the importance to drink water 
and electrolyte containing fluids throughout the day when diarrhea occurs. If IV fluids are needed, their 
administration must be recorded on the eCRF. 
 
Prophylaxis with bowel motility agents should follow institutional practice as applied to drugs such as 
vincristine, including the use of agents such as stool softeners, bulking agents, stimulating agents and/or 
dopamine antagonists. The use of opiates should be limited to when clearly indicated and prophylaxis 
for opiate induced constipation with agents such as methylnaltrexone should be administered. If 
significant constipation develops, it should be managed immediately and plinabulin administration 
should be delayed until resolution. Careful observance for signs of ileus and early diagnostic evaluation 
with radiographic and/or ultrasound studies is recommended. 
6.5.1 Suggested supportive care measures for the management of adverse events that are related 
to nivolumab or ipilimumab 
Immuno-oncology (I-O) agents are associated with AEs that can differ in severity and duration than AEs 
caused by other therapeutic classes. Nivolumab and ipilimumab are considered immuno-oncology 
agents in this protocol. Early recognition and management of AEs associated with immuno-oncology 
agents may mitigate severe toxicity. Management algorithms have been developed to assist investigators 
in assessing and managing the following groups of AEs: Gastrointestinal, Renal, Pulmonary, Hepatic, 
Endocrinopathies, Skin, Neurological. 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 31 of 77 For subjects expected to require more than 4 weeks of corticosteroids or other immunosuppressants to 
manage an AE, consider recommendations provided in the algorithms. These algorithms are found in 
Appendix 1. The guidance provided in these algorithms should not replace the Investigator’s medical 
judgment but should complement it. 
 
Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at 
start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of 
oral corticosteroids should be taken into account when switching to the equivalent dose of oral 
corticosteroids.  
 
Patients who are started on steroids for management of an immune-related event should not resume 
immunotherapy until steroids have been tapered to ≤ prednisone 10mg daily or an equivalent dose of an 
alternative corticosteroid.  
 
 Management of Infusion Reactions:   Acute infusion reactions (which can include cytokine release 
syndrome, angioedema, or anaphylaxis) are different from allergic/hypersensitive reactions, although 
some of the manifestations are common to both AEs.  
 
The table below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of nivolumab. 
 
Management of Infusion Related Reaction (IRR), Allergic Reaction, 
Hypersensitivity reaction or Bronchospasm from Nivolumab or Ipilimumab 
Description  Action 
CTCAE Grade 1 
IRR, allergic reaction 
or bronchospasm1  Remain at bedside and monitor subject until recovery from symptoms. 
CTCAE Grade 2 
IRR, allergic reaction 
or bronchospasm1  Stop the infusion, begin an IV infusion of normal saline, and treat the 
subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 
325 to 1000 mg (acetaminophen); remain at bedside and monitor subject 
until resolution of symptoms. Corticosteroid or bronchodilator therapy may 
also be administered as appropriate. If the infusion is interrupted, then 
restart the infusion at 50% of the original infusion rate when symptoms 
resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor subject closely. If 
symptoms recur, then no further nivolumab will be administered at that 
visit. Administer diphenhydramine 50 mg IV, and remain at bedside and 
monitor the subject until resolution of symptoms. The amount of study drug 
infused must be recorded on the electronic case report form (eCRF).  
CTCAE Grade 3 or 4 
IRR, allergic 
reaction, 
bronchospasm or 
hypersensitivity 
reaction2  Immediately discontinue infusion of nivolumab. Begin an IV infusion of 
normal saline, and treat the subject as follows. Recommend bronchodilators, 
epinephrine 0.2 to 1 mg of a 1:1,000 solution for subcutaneous 
administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for 
IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should 
be monitored until the investigator is comfortable that the symptoms will 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 32 of 77 not recur. Nivolumab or ipilimumab will be permanently discontinued . 
Investigators should follow their institutional guidelines for the treatment of 
anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. In the case of late-occurring hypersensitivity symptoms (eg, 
appearance of a localized or generalized pruritis within 1 week after 
treatment), symptomatic treatment may be given (eg, oral antihistamine, or 
corticosteroids).  
1For any ≤Grade 2 IRR, allergic reaction or bronchospasm, see Section 5.1.2 for recommended premedication 
for subsequent infusions.  
2Hypersensitivity reactions included in CTCAEv4 include anaphylaxis, Stevens-Johnson syndrome and toxic 
epidermal necrolysis; in the case of late-occurring hypersensitivity symptoms (e.g., appearance of a localized or 
generalized pruritis within 1 week after treatment), symptomatic treatment may be given (e.g., oral 
antihistamine, or corticosteroids).  
 
7. TOXICITIES AND DOSE DELAYS/DOSE MODIFICATIONS 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v4 will be used to grade adverse 
events.  Subjects enrolled in this study will be evaluated clinically and with standard laboratory tests 
before and at regular intervals during their participation in this study as specified in Study Calendar & 
Evaluations. Subjects will be evaluated for adverse events (all grades), serious adverse events, and 
adverse events requiring study drug interruption or discontinuation as specified in Study Calendar & 
Evaluations.   
7.1 Dose Delays/Dose Modifications 
In the event of multiple toxicities, dose delays and modifications should occur in accordance with the 
highest grade of AEs observed. 
All patients with evidence of radiographically confirmed progressive disease or clinical evidence of 
disease progression or global deterioration of health unrelated to progressive disease, as defined by 
RECIST version 1.1, will be discontinued from study treatment. 
7.1.1 Criteria for Treatment 
In the absence of disease progression, laboratory tests are required prior to Day 1 of each cycle as per 
the schedule of assessments. The follow criteria must be met: 
 
 AST ≤ 3 ULN, ALT ≤ 3 ULN (≤ 1.5 x ULN if alkaline phosphatase is > 2.5 x ULN) 
 Serum bilirubin ≤ 1.5 x ULN (unless patient has Gilbert’s disease, then bilirubin ≤ 3.0 x ULN) 
 Creatinine ≤ 1.5 x ULN 
 Hemoglobin ≥ 9 g/dL 
 Absolute neutrophil count ≥ 1.0 x 109/L 
 Platelets ≥ 100 x 109/L 
7.1.2 Plinabulin 
The dose levels and the general approach to dose delay and modification of plinabulin are shown below. 
Plinabulin dosing must be withheld if the patient has evidence or signs of any medical condition that 
would prevent dosing (such as an infection, grade 4 neutropenia, or unacceptable medical condition). 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 33 of 77 At the discretion of the Investigator, the dose may be delayed for up to 6 weeks for any toxicity possibly 
or probably related to plinabulin that does not meet DLT criteria. Dosage interruptions to assess or treat 
intercurrent illnesses are allowed and should be clearly described in the study eCRF. A delay greater 
than 6 weeks will require the patient to be removed from the study (except in case of potential patient 
benefit, which must be approved by the Sponsor Investigator). 
 
Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 34 of 77 Table 3 Plinabulin Dose Delay and Modification Guidelines  
Adverse 
Reaction Provide Supportive 
Care for: Withhold 
Plinabulin For: Permanently Discontinue 
Plinabulin For: 
Infusion 
related 
reaction Grade 2: Stop the infusion, begin an IV infusion of 
normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or 
acetaminophen 325 to 1000 mg; remain at bedside 
and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be 
administered as appropriate. If the infusion is 
interrupted, restart the infusion at 50% of the original 
infusion rate when symptoms resolve. Monitor 
subject closely. If symptoms recur, then no further 
plinabulin will be administered at that visit. 
Administer diphenhydramine 50 mg IV, remain at 
bedside and monitor the subject until resolution of 
symptoms. The amount of study drug infused must 
be recorded on the electronic case report form 
(eCRF). Consider premedicating with 
dexamethasone 2 to 4 mg daily on days -1, 1, 2 of 
treatment for subsequent cycles.   Grade 3 or 4:  Immediately discontinue 
infusion of plinabulin Begin an IV infusion of 
normal saline and treat the subject as follows.  
 Recommend bronchodilators, epinephrine 0.2 
to 1 mg of a 1:1,000 solution for 
subcutaneous administration or 0.1 to 0.25 
mg of a 1:10,000 solution injected slowly for 
IV administration, and/or diphenhydramine 
50 mg IV with methylprednisolone 100 mg 
IV (or equivalent), as needed. Subject should 
be monitored until the investigator is 
comfortable that the symptoms will not recur. 
Investigators should follow their institutional 
guidelines for the treatment of anaphylaxis. 
Remain at bedside and monitor subject until 
recovery from symptoms. In the case of late-
occurring hypersensitivity symptoms (eg, 
appearance of a localized or generalized 
pruritis within 1 week after treatment), 
symptomatic treatment may be given (eg, 
oral antihistamine, or corticosteroids).  
Cytokine 
release 
syndrome Management of symptoms such as fever and muscle 
pain with acetaminophen or other analgesic. 
Consider oxygen therapy, fluids and antihypotensive 
agents (if hypotensive) for grade 2 or higher. 
 
For grade 2 symptoms that do not resolve or for 
grade 3 or higher symptoms, high-dose steroids 
should be initiated and patient should be admitted for 
management and observation.  Grade 2:  
May restart plinabulin at one 
dose level lower once 
symptoms resolve. Grade 3 or 4 
Hyperten-
sion For BP > 160 : oral amlodipine 10 mg or an 
equivalent calcium channel blocker should be 
administered before each subsequent dose. Increases  First occurrence of BP > 
140 and <160 with the use 
of anti-hypertensives .  Second occurrence of BP >140 and <160 
with use of antihypertensive and one dose 
reduction  
Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 35 of 77 Adverse 
Reaction Provide Supportive 
Care for: Withhold 
Plinabulin For: Permanently Discontinue 
Plinabulin For: 
in systolic blood pressure above 200 mmHg should 
be managed with nitroprusside or similar regimen per 
institutional practice  May restart plinabulin at 
one dose level lower with 
anti-hypertensive 
prophylaxis once BP 
returns to grade 1 or better  OR 
First occurrence of BP ≥ 160in spite of anti-
hypertensives. 
Diarrhea Grade 1 or 2 diarrhea. Institute symptomatic 
treatment including hydration, electrolyte 
replacement, dietary changes, and loperamide or 
other per institutional guidelines.   First occurrence of grade 3 
event. Withhold plinabulin 
and institute symptomatic 
treatment.  Plinabulin may 
be restarted at the same 
dose level once toxicity 
resolved to grade 1 or 
better if SYMPTOMATIC 
treatment controlled 
diarrhea. 
 Grade 3 event in patients 
on optimal symptomatic 
treatment: Withhold 
plinabulin and restart at 
one dose level lower once 
event resolves to grade 1 
or better.  Any grade 4 event. 
 Recurrence of grade 3 diarrhea after one dose 
reduction and optimal symptomatic treatment  
 
Table 4 Plinabulin Dose Reduction Levels 
Dose Level Plinabulin dose 
-1 13.5 mg/m2 
1 20 mg/m2 
2 30 mg/m2 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 36 of 77 7.1.3 Nivolumab and Ipilimumab 
Treatment with nivolumab and ipilimumab will be held for: 
 Drug-related grade 4 hematological toxicities 
 ≥Grade 3 non-hematological toxicity (except for fatigue, alopecia and vitiligo OR isolated 
laboratory abnormalities with no clinical correlate) 
 Any AE, laboratory abnormality or inter-current illness which, in the judgment of the 
investigator (in consultation with the study monitor), warrants delaying the dose of study 
medication 
 In the event of isolated CNS progression during study treatment, study drug(s) may be withheld 
while palliative treatment is administered, e.g. a standard course of whole brain radiotherapy in 
accordance with institutional practice, and restarted within 1 week after completion of 
radiotherapy. During this time the patient should be fully evaluated for other sites of disease 
progression. If treatment is delayed >6 weeks, the patient must be permanently discontinued 
from all study therapy, except as specified in Dose Discontinuation Criteria. 
 If guidelines for an irAE are not specified in Table 4 below, nivolumab and ipilumumab should 
be held for any ≥grade 3 irAE, and can be resumed if the irAE recovers to grade 0-1. Systemic 
corticosteroids (1-2 mg/kg/day) are indicated for all grade 3 or 4 irAEs if not otherwise 
specified. Steroids should be tapered once symptoms improve to grade 1 or less and tapered 
over at least 1 month. 
If an irAE is suspected, a thorough evaluation should be conducted in an effort to rule out neoplastic, 
infectious, metabolic, toxin or other etiologic causes prior to diagnosing an irAE. Serological, 
immunological and histological (biopsy) data should be considered to support the diagnosis of an 
immune-related toxicity. All irAEs are graded according to CTCAE, version 4. 
Nivolumab and ipilumumab will be permanently discontinued for: 
 Grade ≥3 diarrhea or colitis 
 Grade ≥3 adrenal insufficiency 
 Life-threatening or grade 4 AE 
 Any severe or grade 3 treatment-related AE that recurs 
 Inability to reduce corticosteroid dose to ≤10 mg of prednisolone or equivalent/day within 
6 weeks 
 Persistent grade 2 or 3 treatment-related adverse reactions that do not recover to grade 1 or 
resolve within 6 weeks after last dose. 
 
  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 37 of 77 Table 5 Nivolumab/Ipilumumab Dose Modifications Guidelines  
Adverse 
Reaction Withhold  
Nivolumab/Ipilimumab For: Permanently Discontinue 
Nivolumab/Ipilimumab For: 
Pneumonitis Grade 2 
 
 Promptly initiate empiric steroids 
(prednisone 1-2 mg/kg/day or 
equivalent) 
 If no improvement within 3-5 days, 
additional workup should be 
considered and prompt treatment with 
IV methylprednisolone 2-4 mg/kg/day 
started. If still no improvement within 
3-5 days, promptly start 
immunosuppressive therapy such as 
TNF inhibitors (e.g. infliximab). 
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and in particular, anti PCP treatment  Grade 3 or 4 
 
 Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day 
or equivalent  
 Hospitalize the patient, obtain 
pulmonary consult, supportive care 
(oxygen etc.) 
 If no improvement within 3-5 days, 
additional workup should be 
considered and prompt treatment with 
additional immunosuppressive therapy 
such as TNF inhibitors (e.g. infliximab)  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and in particular, anti PCP treatment  
Hepatitis ≥ Grade 2 if patient has baseline AST, 
ALT or total bilirubin that is within 
normal limits 
 
 Regular checking of LFTs (e.g. every 
1-2 days) until elevations of these are 
improving or resolved.  
 If event is persistent (> 3-5 days) or 
worsens, promptly start prednisone 
1-2 mg/kg/day or IV equivalent.  
 If still no improvement within 3-5 days, 
consider additional workup and prompt 
treatment with IV methylprednisolone 
2-4 mg/kg/day started.  
 If still no improvement within 3-5 days 
despite 2-4 mg/kg/day of IV 
methylprednisolone, promptly start 
immunosuppressives (mycophenolate 
mofetil). Infliximab should NOT be 
used.  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  AST or ALT > 8 x ULN OR total 
bilirubin >5 x ULN OR concurrent AST 
or ALT > 3 x ULN and total bilirubin > 
2 x ULN 
Any grade 4 
 Promptly initiate empiric IV 
methylprednisolone at 1 to 4 mg/kg/day 
or equivalent  
 If still no improvement within 3-5 days, 
promptly start treatment with 
immunosuppressive therapy 
(mycophenolate mofetil). Infliximab 
should NOT be used.  
 Hepatology consult, abdominal 
workup, and imaging as appropriate.  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  
Diarrhea/Colitis Grade 2  Grade 3 or 4 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 38 of 77 Adverse 
Reaction Withhold  
Nivolumab/Ipilimumab For: Permanently Discontinue 
Nivolumab/Ipilimumab For: 
 
 Symptomatic treatment including 
hydration, electrolyte replacement, 
dietary changes, and loperamide and/or 
budesonide. Consider hospitalization if 
grade 3. 
 Promptly start prednisone 1 to 
2 mg/kg/day or IV equivalent  
 If event is not responsive within 3-
5 days or worsens, GI consult should 
be obtained for further workup such as 
imaging and/or colonoscopy, and 
prompt treatment with IV 
methylprednisolone 2-4 mg/kg/day 
started.  
 If still no improvement within 3-5 days 
despite 2-4 mg/kg IV 
methylprednisolone, promptly start 
immunosuppressives such as 
infliximab. Caution: Important to rule 
out bowel perforation and refer to 
infliximab label for general guidance 
before using infliximab  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti P CP treatment   
 Promptly initiate empiric IV 
methylprednisolone 2 to 4 mg/kg/day 
or equivalent  
 Hospitalize patient, urgent GI consult 
and imaging and/or colonoscopy as 
appropriate  
 If still no improvement within 3-5 days, 
promptly start further 
immunosuppressives (e.g. infliximab). 
Caution: Ensure GI consult to rule out 
bowel perforation and refer to 
infliximab label for general guidance 
before using infliximab.  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  
Nephritis and 
renal 
dysfunction Grade 2  
 
 Carefully monitor serum creatinine 
every 2-3 days and as clinically 
warranted  
 Consult Nephrologist and consider 
renal biopsy if clinically indicated  
 If event is persistent (> 3-5 days) or 
worsens, promptly start prednisone 1 to 
2 mg/kg/day or IV equivalent  
 If event is not responsive within 
3-5 days, additional workup should be 
considered and prompt treatment with 
IV methylprednisolone at 2-
4 mg/kg/day started.  
 Once improving gradually taper 
steroids over ≥28 days and consider Grade 3 or 4 
 
 Carefully monitor serum creatinine 
every 1-2 days  
 Consult Nephrologist and consider 
renal biopsy if clinically indicated  
 Promptly start prednisone 1 to 
2 mg/kg/day or IV equivalent  
 If event is not responsive within 3-
5 days or worsens despite prednisone at 
1-2 mg/kg/day or IV equivalent, 
additional workup should be 
considered and prompt treatment with 
IV methylprednisolone 2-4 mg/kg/day 
started.  
 Once improving, gradually taper 
steroids over ≥28 days and consider 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 39 of 77 Adverse 
Reaction Withhold  
Nivolumab/Ipilimumab For: Permanently Discontinue 
Nivolumab/Ipilimumab For: 
prophylactic antibiotics, antifungals 
and anti PCP treatment  prophylactic antibiotics, antifungals 
and anti PCP treatment  
Rash 
(excluding 
Bullous skin 
formations) 
 
**IF THERE IS 
ANY BULLOUS 
FORMATION, THE 
STUDY 
PHYSICIAN 
SHOULD BE 
CONTACTED AND 
STUDY DRUG 
DISCONTINUED**  Grade 2 or 3 
 
 Obtain dermatology consult  
 Symptomatic topical treatment  
 Consider moderate-strength topical 
steroid  
 If no improvement of rash/skin lesions 
within 3-5 days or is worsening, 
promptly start systemic steroids 
prednisone 1-2 mg/kg/day or IV 
equivalent  
 Consider skin biopsy if persistent for 
>1-2 weeks or recurs 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  Grade 4 
 
 Hospitalize patient and consult 
dermatology  
 Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day 
or equivalent  
 Consider skin biopsy  
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment 
Type I diabetes 
mellitus 
[TIDM] (if new 
onset) or 
Hyperglycemia Grade 2 or 3 
 
 Obtain endocrinology consult  
 Consider short term corticosteroids or 
hormone replacement therapy as 
indicated  
 If no improvement within 3-5 days or is 
worsening, promptly start systemic 
steroids prednisone 1-2 mg/kg/day or 
IV equivalent  
 Consider hospitalization if grade 3 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  Grade 4 
 
 Hospitalize patient and consult 
endocrinology 
 Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day 
or equivalent  
 Administer hormone replacement 
therapy as indicated 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment 
Hypophysitis Grade 2 or 3 
 
 Obtain endocrinology consult  
 Consider short term corticosteroids or 
hormone replacement therapy as 
indicated  
 If no improvement within 3-5 days or is 
worsening, promptly start systemic Grade 4 
 
 Hospitalize patient and consult 
endocrinology 
 Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day 
or equivalent  
 Administer hormone replacement 
therapy as indicated  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 40 of 77 Adverse 
Reaction Withhold  
Nivolumab/Ipilimumab For: Permanently Discontinue 
Nivolumab/Ipilimumab For: 
steroids prednisone 1-2 mg/kg/day or 
IV equivalent  
 Consider hospitalization if grade 3 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment   Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment 
Adrenal 
insufficiency Grade 2  
 
 Obtain endocrinology consult  
 Consider short term corticosteroids or 
hormone replacement therapy as 
indicated  
 If no improvement within 3-5 days or is 
worsening, promptly start systemic 
steroids prednisone 1-2 mg/kg/day or 
IV equivalent  
 Consider hospitalization if grade 3 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  Grade 3 or 4 
 
 Hospitalize patient and consult 
endocrinology 
 Promptly initiate empiric IV 
methylprednisolone 1 to 4 mg/kg/day 
or equivalent  
 Administer hormone replacement 
therapy as indicated 
 Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment 
Immune 
mediated  
Neurotoxicity  Grade 2 
 
 Discuss with the study physician  
 Obtain Neurology Consult  
 Pain medications as indicated  
 Promptly start systemic steroids 
prednisone 1-2mg/kg/day or IV 
equivalent  
 If no improvement within 3-5 days 
despite 1-2 mg/kg/day prednisone or IV 
equivalent consider additional workup 
and promptly treat with additional 
immunosuppressive therapy (e.g. IVIG)  Grade 3 or 4 
 
 Discuss with study physician  
 Hospitalize and obtain Neurology 
Consult  
 Promptly initiate empiric IV 
methylprednisolone 1 to 2 mg/kg/day 
or equivalent  
 If no improvement within 3-5 days 
despite IV corticosteroids, consider 
additional workup and promptly treat 
with additional immunosuppressants 
(e.g. IVIG)  
 Once stable, gradually taper steroids 
over ≥4 weeks  
Uveitis ≥ Grade 2 
 
 - Obtain ophthalmology consult  
 - Promptly initiate topical steroids  
 - If no improvement within 3-5 days or 
is worsening, promptly start systemic ≥ Grade 2 (if not improving to grade 1 
within 2 weeks while receiving topical 
treatment OR requiring systemic 
treatment) 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 41 of 77 Adverse 
Reaction Withhold  
Nivolumab/Ipilimumab For: Permanently Discontinue 
Nivolumab/Ipilimumab For: 
steroids prednisone 1-2 mg/kg/day or 
IV equivalent  
 - Once improving gradually taper 
steroids over ≥28 days and consider 
prophylactic antibiotics, antifungals 
and anti PCP treatment  
There are no dose recommendations for hypothyroidism or hyperthyroidism. Isolated grade 4 amylase or 
lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis and 
decrease to <grade 4 within 1 week of onset do not require treatment modifications. If the decision is 
made to resume dosing, the patient should restart treatment on the next regularly scheduled dosing visit. 
Skipped doses are not to be replaced. 
Patients should receive appropriate supportive care measures as deemed necessary by the Investigator. 
For further recommendations, see the “Immune Mediated Adverse Reaction Management Guide” 
(Bristol-Myers Squibb 2017 ). 
7.2 Protocol Discontinuation 
If a subject decides to withdraw from the study (and not just from protocol therapy) all efforts should be 
made to complete the final study assessments. The site study team should contact the subject by 
telephone or through a clinic visit to determine the reason for the study withdrawal. If the reason for 
withdrawal is an adverse event, it will be recorded on the eCRF. 
Big Ten Cancer Research Consortium     Clinical Study Protocol 
         BTCRC-LUN17-127  
27APR2022 Confidential Page 42 of 77 8. CALENDAR & EVALUATIONS 
 Screen Cycle = 21 days2 Cycle = 14 days2 Safety 
follow up Long-term 
Follow up Cycle 1 Cycles 2-4  Cycle 5+ 
-28 
days1 D1 D1 D1 30 days 
post Tx Q 3 months 
(±14 days) 
REQUIRED  ASSESSMENTS       
Informed Consent  X      
Medical history , smoking history, trial awareness , prior NGS16 X      
Diagnosis and Staging3 X      
AEs (esp. constipation) & Concomitant Medications4 X X X X +30,+100   
PE, VS, ECOG PS , weight, height (screen only)5 X X X X X  
Electrocardiogram  X    X  
LABORATORY ASSESSMENTS       
Complete Blood Count, Chemistry6 X X X X X  
LDH, Lipase, Amylase6 X X X X X  
PT, PTT, INR  X      
Hepatitis B and C test ing7 X      
ACTH, TSH, T3/T48 X X X Every odd cycle X  
Urinalysis X      
Pregnancy test WOCBP9 -14 d X X X   
DISEASE ASSESSMENT       
Disease Imaging10 X  post C2, C4  Q4 cycles   
TREATMENT EXPOSURE       
Nivolumab : 1 mg/kg   X X    
Nivolumab: 240 mg flat dose     X   
Ipilimumab : 3 mg/kg   X X    
Plinabulin11: PhI escalating cohorts ; Ph II 30 mg/m2  X5 X5 X5   
CORRELATIVE STUDIES (SPECIMEN COLLECTION)      
Whole blood for hsCRP, ESR, SAA; haptoglobin & cytokine 
levels (Ph.II only)12  X X X X  
Whole Blood for PBMCs and Plasma13  X C3D1  X  
BANKING SAMPLES (SPECIMEN COLLECTION)       
Whole Blood , Serum and Plasma14  X  C5D1 X  
Unstained Slides15 X    Bx@PD  
FOLLOW-UP        
Survival status, subsequent therapy       X 
  
Big Ten Cancer Research Consortium     Clinical Study Protocol 
         BTCRC-LUN17-127  
27APR2022 Confidential Page 43 of 77 Key to Footnotes  
1. Screening (baseline) labs performed within 7 days of C1D1 treatment do not need to be repeated.   
2. A window of ±3 days will be applied to all treatment visits; a window of ±7 days will apply for all safety follow-up visits and tumor imaging. 
3. Diagnosis and staging to include pathology report and Tumor Node Metastasis (TNM) staging 
4. AEs and Conmeds: Patients should specifically be asked about signs of constipation and treatment provided when indicated. A safety follow-
up visit will occur 30 days (±7 days) after the last dose of treatment. An additional assessment of AEs will be performed 100 days (±14 days) 
after last dose of study drugs. Patients with drug related AEs of ≥grade 2 observed at the 30-day safety assessment, should be followed-up 
monthly during clinical visits until the AE has resolved to grade 1, the event is believed to be chronic, or patient receives other anti-cancer 
therapy, whichever occurs first. Concomitant medications are to be recorded up to the 30-day Safety Visit. Concomitant medications should 
only be recorded after the safety visit if it relates to an unresolved AE. 
5. Physical Exam (PE), Vital Signs (VS), ECOG Performance Status (PS), weight, and height (screening only). Vital signs include: temperature, 
blood pressure, heart rate, and respiratory rate. Vital signs should be measured immediately before, after (±10 min), and 30 and 60 minutes 
following the plinabulin infusion on Cycle 1 Day 1. Thereafter, vital signs are collected immediately before and after each infusion. 
6. CBC to include : hemoglobin, hematocrit, red blood cell and white blood cell counts with differential and platelets. CBC may be monitored on 
a more frequent basis, in accordance with institutional guidelines, should a patient have grade 4 hematologic AEs. Chemistry to include : 
sodium, potassium, bicarbonate, chloride, bicarbonate, calcium, magnesium, glucose, urea Nitrogen, creatinine, alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, total protein, albumin, lipase, amylase, and total bilirubin (plus direct 
bilirubin if total bilirubin is elevated).  
7. Hepatitis B and C tests include hepatitis B surface antigen, antibody to the hepatitis B core antigen, and hepatitis C virus antibody. Results that 
may be consistent with chronic or active infection must be confirmed by PCR tests for hepatitis B and/or C. 
8. Adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), and triiodothyronine (T3) and/or free thyroxine (free T4); free or 
total T3/T4 will be performed as per local standards.  
9. Women of childbearing potential must have a negative urine pregnancy test within 14 days of study registration and within 24-hours prior to 
each plinabulin infusion. Positive urine tests should be confirmed with a serum test. 
10. Perform CT scan of the abdomen/pelvis, CT of the chest, or additional staging as required for each patient. A bone scan will only be 
performed in patients with known bone metastasis at study entry to monitor the status of metastatic disease in bone. Target and non-target 
lesion response and overall disease response are to be assessed (RECIST 1.1) after cycle 2 and after cycle 4. After that, assess every 4 cycles 
(post C8, C12, etc.). End of treatment tumor assessment will be done at the discretion of the treating physician.  
11. Plinabulin will be administered 60 minutes after end of ipilimumab infusion (Cycles 1 to 4) or 30 minutes after end of nivolumab infusion 
(maintenance period). Vital signs will be assessed as per footnote #5.  
12. Mandatory whole blood for high sensitivity C-reactive protein [hsCRP], erythrocyte sedimentation rate [ESR], serum amyloid A [SAA].  
Phase II only: Mandatory whole blood for haptoglobin and cytokine levels in addition to the labs above for Ph 2 subjects on D1 of every cycle. 
13. Mandatory whole blood for PBMCs and plasma for banking to be collected pre-Treatment C1D1, C3D1, and at safety follow up. See CLM for 
collection, processing, labeling, and shipping instructions. 
14. Optional whole blood, serum and plasma for banking are to be collected at Pre-Treatment Cycle 1 Day 1, pre-treatment Cycle 5 Day 1, and at 
30-day safety follow up visit. See CLM for collection, processing, labeling and shipping instructions. 
15. Optional submission of unstained slides for banking from an archived FFPE tumor block or fresh biopsy. At disease progression, an optional 
tumor biopsy may be performed and tumor sample stored for banking. See CLM for collection, labeling, and shipping instructions. 
16. Prior NGS/genetic testing results for tumor mutational burden are requested, if available. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 44 of 77 8.1 Study Assessments and Procedures 
Informed consent must be obtained before any study-specific samples are taken or study-specific tests or 
evaluations are conducted. Screening/baseline assessments should be performed within 28 days of study 
registration. Study eligibility will be based on satisfying all of the study inclusion and exclusion criteria. 
The patient’s cancer diagnosis including prior treatment and the patient’s demographics will be 
documented. Test results performed as part of standard of care within the required time frame may be 
used in lieu of repeating the tests required for eligibility. 
8.1.1 Laboratory and Other Assessments 
1. Hematology:  Hemoglobin, hematocrit, red blood cell count (RBC), white blood cell count 
(WBC) with differential, and platelet count will be obtained for all treatment cycles. WBC 
(including differential) outside of normal range can be retested to determine eligibility. Complete 
blood count (CBC) will be monitored on a more frequent basis, in accordance with institutional 
guidelines, should a patient have grade 4 hematological AEs. Results of all baseline tests must be 
reviewed for eligibility by the treating Investigator or their designee prior to registration. In 
addition, results of hemoglobin, absolute neutrophil count, and platelet count must be reviewed 
prior to each infusion.  
2. Blood chemistry/electrolytes: Sodium, potassium, chloride, bicarbonate, calcium, magnesium, 
glucose, BUN, serum creatinine, ALT, AST, alkaline phosphatase, LDH, total protein, albumin, 
lipase, amylase, and total bilirubin (plus direct bilirubin if total bilirubin is elevated).  
Results of all baseline tests must be reviewed for eligibility by the treating Investigator or their 
designee prior to registration. Results of AST, ALT, AP, bilirubin, and creatinine must be 
reviewed prior to each infusion. 
3. Pregnancy test:  Urine dipstick pregnancy tests are to be performed for females of childbearing 
potential at each treatment visit. Positive urine tests are to be confirmed with serum pregnancy 
testing. 
4. Urinalysis : Glucose, blood, protein and pH. If blood or protein in urine is present, a microscopic 
examination is required. Results of all baseline tests must be reviewed for eligibility by the 
treating Investigator or their designee prior to registration.  
5. Endocrine tests : Including adrenocorticotropic hormone (ACTH), thyroid stimulating hormone 
(TSH), and T3 and/or T4 (free or total will be performed as per local standards). 
8.1.2 Prior and Concomitant Medications 
All concomitant medications will be recorded from the time the patient signs the informed consent form 
until discontinuation of treatment. Concomitant medications will only be collected after treatment 
discontinuation if it is associated with an on ongoing AE. 
8.2 Screening Visit and Baseline (Within 28 Days Prior to Registration) 
At the screening visit, information will be collected and patients will have clinical evaluations as 
follows: 
 Informed consent 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 45 of 77  Medical history (including events up until treatment); demographics; smoking history; trial 
awareness question; prior NGS/genetic testing 
 Diagnosis and staging 
 Tumor assessments and measurement 
 Concomitant medications (starting from the time the patient signs the informed consent) 
 Complete physical examination, including height (screen only) and weight 
 Vital sign measurements 
 ECOG Performance status; 
 Baseline electrocardiogram (ECG) 
 Hematology, serum chemistry and urinalysis, endocrine labs, coagulation tests, Hepatitis B and 
C tests 
 Inflammation serum biomarkers 
 Urine pregnancy test, if applicable (positive results to be confirmed by serum pregnancy testing) 
 Unstained slides: 
o For banking (with subject consent) 
8.3 On Treatment Evaluations 
8.3.1 Day 1 of Each Cycle 
 Concomitant medications 
 Physical examination 
 Vital sign measurements 
 ECOG Performance status 
 Hematology, serum chemistry,  
 Endocrine labs (every odd cycle after first 4 cycles) 
 Inflammation serum biomarkers 
 Urine pregnancy test, if applicable (positive results to be confirmed by serum pregnancy testing) 
 Nivolumab infusion 
 Ipilimumab infusion (Cycles 1-4 only) 
 Plinabulin infusion 
 AEs. Patients should specifically be asked about signs of constipation and treatment provided 
when indicated. 
 Whole blood for hsCRP, ESR, SAA (mandatory). Ph 2: haptoglobin and cytokine levels. 
 Cycle 1 and Cycle 3 only: Whole blood for PBMC (mandatory) and plasma isolation for banking 
(with subject consent) 
 Cycle 1 and 5 only: Whole blood, serum and plasma for banking (with subject consent) 
8.3.2 Post Cycle 2, Cycle 4 and Every 4 Cycles Thereafter 
 Disease assessment after cycle 2 and after cycle 4. After that, assessments will be done every 4 
cycles (post C8, C12, etc.). 
8.4 Protocol Discontinuation and Assessment 
In addition to discontinuation from treatment related toxicities as described in Section 7, a subject will 
also be discontinued from protocol therapy and followed up per protocol under the circumstances 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 46 of 77 outlined below. The reason for discontinuation of protocol therapy will be documented on the electronic 
case report form (eCRF). 
 Documented disease progression  
 The treating physician thinks a change of therapy would be in the best interest of the subject 
 The subject requests to discontinue protocol therapy, whether due to unacceptable toxicity or for 
other reasons 
o If a subject decides to prematurely discontinue protocol therapy (“refuses treatment”), the 
subject should be asked if he or she may still be contacted for further scheduled study 
assessments. The outcome of that discussion should be documented in both the medical 
records and in the eCRF. 
 A female subject becomes pregnant  
 If plinabulin or nivolumab is interrupted for ≥ 6 weeks. 
All patients who have received at least 1 dose of study drug and have discontinued treatment for any 
reason will have an 30-day Safety assessment performed.  
The Safety Follow up assessments should include the following: 
 Concomitant medications 
 Complete physical examination, including weight 
 Vital signs measurements  
 ECOG Performance Status 
 Electrocardiogram (ECG) 
 Hematology, serum chemistry, endocrine labs 
 Inflammation serum biomarkers 
 AEs 
 Disease assessment should be done at the discretion of the treating physician. 
 Whole blood for hsCRP, ESR, SAA (mandatory). Ph 2: haptoglobin and cytokine levels. 
 Whole blood for PBMC (mandatory) and plasma isolation for banking (with subject consent) 
 Whole blood, serum and plasma for banking (with subject consent) 
 Optional biopsy: At disease progression, tumor biopsy may be performed and tumor sample 
stored for banking. 
An additional assessment of AEs will be performed 100 days (±14 days) after last dose of study drugs. 
8.5 Surgery or Radiation Therapy 
Treatment of isolated/symptomatic lesions by local surgery or radiation therapy is permitted for 
palliative or potentially curative management at any time beyond Cycle 2. Radiation should not be given 
within 7 days prior to plinabulin administration. Surgery should be performed after holding plinabulin 
for 21 days and can be resumed 21 days after surgery. All interventions must be discussed in advance 
with the Sponsor Investigator. 
8.5.1 Adverse Event Assessments 
Information regarding the occurrence of SAEs will be collected from the time the patient signs the 
informed consent form. AEs will be collected after registration. SAEs and AEs will be collected 
throughout their participation in the study, including a period of 100 days after the patient’s last active 
dose of study drug, unless a new treatment has been started. SAEs that occurs more than 100 days after 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 47 of 77 the last dose of study drug need not be reported unless the Investigator considers them related to study 
drug. 
8.6 Safety Follow-up Evaluations 
For the purpose of this study, all AEs irrespective of causality will be collected from registration. A 
safety follow-up visit should occur when subjects permanently stop study treatment for whatever reason 
(toxicity, progression, or at discretion of site investigator) and should be performed 30 days and 100 
days (±7 days) after the last dose of treatment. Subjects who have an ongoing ≥ grade 2 or serious AE 
(SAE) at this visit will continue to be followed until the AE resolves to ≤ Grade 1 or baseline, is deemed 
clinically insignificant, and/or until a new anti-cancer treatment starts, whichever is earlier. 
8.7 Long Term Follow-up Evaluations 
All patients (phase I and phase II) will be followed at least every 3 months (±7 days) for survival for up 
to one year following their Safety Follow up visit, unless the trial is completed or terminated or 
informed consent is withdrawn. Follow up will continue even if the patient receives another anticancer 
therapy. Patients can consent to participate in follow-up assessments even if consent for study 
participation has been withdrawn. 
 
If patient discontinues study therapy for a reason other than progression, disease assessment will 
continue until disease progression is found or the patient initiates next treatment, whichever occurs first.  
 
Follow up may be accomplished via clinic visit, phone call, or other avenues as appropriate. 
9. BIOSPECIMEN STUDIES AND PROCEDURES 
9.1 Biomarkers of Inflammation and Cytokine Panels 
Levels of (high sensitivity C-reactive protein [hsCRP], erythrocyte sedimentation rate [ESR], serum 
amyloid A [SAA]) in whole blood will be measured on day 1 of each cycle and at the Safety Follow up 
visit for all subjects. In addition, phase 2 subjects will also have blood drawn for haptoglobin analysis 
and cytokine levels.  Haptoglobin and cytokine levels in whole blood will be measured on day 1 of each 
cycle and at the Safety Follow up visit.   
 
The following cytokine and chemokine panels will be considered, but other cytokine and/or chemokine 
panels may be considered in the future: 
 Proinflammatory panel: 10plex (IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, 
and TNF-α 
 Cytokine panel: 10plex (GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, 
TNF-β, and VEGF-A) 
 Chemokine panel: Eotaxin, Eotaxin-3, IL-8, IL-8 (HA), IP-10, MCP-1, MCP-4, MDC, MIP-1α, 
MIP-1β, TARC 
 CCL5 (RANTES): single chemokine analysis 
 
All of these analyses will be done at LabCorp (formerly known as Covance laboratories). Refer to the 
CLM for collection, processing, labeling and shipping instructions. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 48 of 77 9.2 Tumor Mutation burden 
The tumor mutational burden will be correlated with PFS and ORR. Tumor mutation burden will be 
measured using next generation sequencing based on in vitro diagnostic tests. Prior NGS/genetic testing 
results (if available) will be requested at the time of patient enrollment on study. Information about the 
main cancer-related gene alterations from the next gen sequencing results will also be collected for 
exploratory purposes. 
9.3 Immunophenotyping/Immune Repertoire TCR Sequencing 
Whole blood for PBMCs and plasma isolation will be collected at pre-treatment C1D1, C3D1, and at the 
safety follow up visit and shipped overnight for processing. PBMCs will be cryopreserved prior to 
analysis.  Cryopreserved PBMCs will be used for immunophenotyping by flow cytometry and immune 
repertoire TCR sequencing. 
9.4 Banking of Leftover Biospecimens 
Subject consent will be obtained to bank any leftover samples that were collected for study-specific 
correlative research. Hoosier Cancer Research Network (HCRN), as Administrative Headquarters for 
the Big Ten CRC, will manage the banked samples. Samples will be banked indefinitely in the Hoosier 
Cancer Research Network Biorepository and used for future unspecified cancer-related research. 
9.5 Samples for future unspecified studies 
Subject consent will be obtained to collect additional samples for future unspecified Big Ten Cancer 
Research Consortium studies. Hoosier Cancer Research Network, as Administrative Headquarters for 
the Big Ten CRC, will manage the banked samples. Samples will be banked indefinitely in the Hoosier 
Cancer Research Network Biorepository.  
 
This includes: 
 Whole blood: Whole blood will be collected prior to treatment on Cycle 1 Day 1, Cycle 5 Day 1 and 
at 30-day safety follow up visit.  
 Pre- and Post-treatment plasma: Whole blood for plasma will be collected prior to treatment on Cycle 
1 Day 1, Cycle 5 Day 1 and at the 30-day Safety Follow-up visit.  
 Pre- and Post-treatment serum: Whole blood for serum will be collected prior to treatment on Cycle 1 
Day 1, Cycle 5 Day 1 and at the 30-day Safety Follow-up visit. 
 Unstained slides: Unstained slides will be obtained from the subject’s archived formalin fixed paraffin 
embedded tumor sample or fresh biopsy. At disease progression, an optional tumor biopsy may be 
performed and tumor sample stored for banking. 
 
Please refer to the Correlative Laboratory Manual (CLM) for all sample collection, processing, labeling, 
and shipping instructions. 
9.6 Confidentiality of Biospecimens 
Samples will be identified by a subject’s study number assigned at the time of registration to the trial. 
Any material issued to collaborating researchers will be anonymized and only identified by the subject’s 
study number. 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 49 of 77 10. CRITERIA FOR DISEASE EVALUATION 
For the purposes of this study, all tumor assessments must be completed following the same 
methodology as used for the screening assessment. Methodology and disease response will be assessed 
as specified in RECIST 1.1 guidelines. During study treatment, disease status will be assessed after 
cycle 2 and after cycle 4. After that, assess every 4 cycles (post C8, C12, etc.). Perform CT scan of the 
abdomen/pelvis, CT of the chest, or additional staging as required for each patient. A bone scan will 
only be performed in patients with known bone metastasis at study entry to monitor the status of 
metastatic disease in bone. If radiologic imaging shows progressive disease (PD), tumor assessment may 
be repeated approximately 4-6 weeks later in order to confirm continued PD (as compared to the initial 
scan). Treatment may continue at the discretion of the treating physician while awaiting radiologic 
confirmation of progression. If repeat imaging shows a reduction or stabilization in the tumor burden 
compared to the initial scan demonstrating PD, treatment may be continued as per treatment calendar. 
10.1 Measurable Disease 
Measurable disease is defined as the presence of at least one measurable lesion. Measurable lesions are 
defined as those that can be accurately measured in at least one dimension (longest diameter to be 
recorded) as >20 mm by chest x-ray, as >10 mm with CT scan, or >10 mm with calipers by clinical 
exam.  All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters). 
10.1.1 Malignant Lymph Nodes 
To be considered pathologically enlarged and measurable, a lymph node must be >15 mm in short axis 
when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).  At 
baseline and in follow-up, only the short axis will be measured and followed. 
10.2 Non-measurable Lesions 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological 
lymph nodes with ≥ 10 to <15 mm short axis), are considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, 
inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as 
non-measurable. 
 
NOTE:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, 
simple cysts. ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same subject, these are preferred for selection as target lesions. 
10.3 Target Lesions 
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of 
all involved organs, should be identified as target lesions and recorded and measured at baseline.  Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be representative 
of all involved organs, but in addition should be those that lend themselves to reproducible repeated 
measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to 
reproducible measurement in which circumstance the next largest lesion which can be measured 
reproducibly should be selected.  A sum of the diameters (longest for non-nodal lesions, short axis for 
nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 50 of 77 lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease. 
10.4 Non-target Lesions 
All other lesions (or sites of disease) including any measurable lesions over and above the 5 target 
lesions should be identified as non-target lesions and should also be recorded at baseline.  Measurements 
of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of 
each should be noted throughout follow-up. 
10.5 Evaluation of Target Lesions 
NOTE: In addition to the information below, also see section 4.3.2 in the international criteria proposed 
by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee, version 1.1 (Eur J Cancer 
45;2009:228-247) for special notes on the assessment of target lesions.  
 
Complete 
Response (CR) Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non-target) must have reduction in 
short axis to <10 mm.  
Partial Response 
(PR) At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters  
Progressive 
Disease (PD) At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.  (Note:  the 
appearance of one or more new lesions is also considered 
progressions).  
Stable Disease 
(SD) Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum 
diameters while on study  
10.6 Evaluation of Non-target Lesions 
Complete Response (CR) Disappearance of all non-target lesions and 
normalization of tumor marker level.  All lymph 
nodes must be non-pathological in size (<10 mm 
short axis) 
 
Note:  If tumor markers are initially above the upper 
normal limit, they must normalize for a subject to be 
considered in complete clinical response.  
Non-CR/ Non-PD Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal 
limits 
Progressive Disease (PD) Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target 
lesions.  Unequivocal progression should not 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 51 of 77 normally trump target lesion status.  It must be 
representative of overall disease status change, not a 
single lesion increase.  
 
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the site 
investigator should prevail in such circumstances, and the progression status should be confirmed at a 
later time by the sponsor investigator. 
10.7 Evaluation of Best Overall Response 
Target Lesions Non-Target Lesions New Lesions  Overall 
Response 
CR CR No CR 
CR Non-CR/ Non-PD No PR 
CR Not evaluated No PR 
PR Non-PD/ or not all 
evaluated No PR 
SD Non-PD or not all evaluated No SD 
Not all evaluated  Non-PD No Non-evaluable 
PD Any Yes or No PD 
Any PD* Yes or No PD 
Any Any Yes PD 
*In exceptional circumstances, unequivocal progression in non-target lesions may be 
accepted as disease progression.  
 
Subjects with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be classified as having “symptomatic 
deterioration”.  Every effort should be made to document the objective progression even after 
discontinuation of treatment. 
 
In some circumstances it may be difficult to distinguish residual disease from normal tissue.  When the 
evaluation of complete response depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status. 
 
11. DRUG INFORMATION 
11.1 Plinabulin 
The clinical formulation of plinabulin will be supplied as a clear, yellow/orange solution in amber vials 
containing 40mg of drug in 10mL or 80 mg of drug in 20 mL (4 mg/mL). 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 52 of 77 11.1.1 Drug Administration 
The calculated dose (mg) of plinabulin (at a concentration of 4 mg/mL in the vial) is diluted in dextrose 
5% in water (D5W) and administered IV with an in-line filter peripherally or centrally. The diluted dose 
must be used within 6 hours of dilution. Plinabulin must be protected from light at all times (storage, 
prior to, during and after dilution). Instructions for pharmacy drug preparation can be found in the study 
Pharmacy Manual. The plinabulin dose should be calculated based on the baseline BSA, as described in 
Section 6. If BSA subsequently varies from baseline by more than ±10%, then the newer BSA value 
should be used for calculation of subsequent doses. 
11.1.2 Storage and Stability 
Plinabulin must be stored at room temperature and protected from light. Each vial is designated for 
single use. Vials should be stored upright. 
11.1.3 Source of Drug 
Plinabulin is an investigational drug that will be supplied by BeyondSpring Pharmaceuticals, Inc. at no 
charge to subjects participating in this clinical trial. 
11.1.4 Product Accountability 
The designated pharmacist will acknowledge receipt of the drug shipment and note content and 
condition of the package and vials on the clinical material shipping form. Refer to the Pharmacy Manual 
for further information. 
All expired or unused medication will be destroyed on site according to site procedures. Big Ten CRC 
will be notified prior to destruction.  
The pharmacist or person responsible for dispensing the study drug at the site will maintain an accurate 
and current record of all drug supplies received and dispensed to study patients. See Documents/Info tab 
of the EDC for sample dispensing record. 
11.1.5 Adverse Events 
Two clinical studies with plinabulin have been conducted to date, a Phase I monotherapy study and a 
Phase I/II combination study with docetaxel in NSCLC. A total of 141 patients with advanced cancer 
received plinabulin.  
 
In the Phase I monotherapy study (NPI-2358-100), plinabulin was generally well tolerated. AEs 
occurring in ≥ 20% of patients included nausea (61%), vomiting (47%), diarrhea and fatigue (34% 
respectively), constipation, pyrexia, and headache (26% respectively), anorexia (24%), and anemia 
(21%). Overall, 16 patients (42%) experienced serious adverse events (SAEs), the majority were 
considered not related to plinabulin.  
 
In the Phase I/II combination study with docetaxel, plinabulin was also found to be generally well 
tolerated. The combination appeared to have a similar AE profile as single-agent docetaxel. In patients 
receiving plinabulin/docetaxel (DN) at 30 mg/m2 of plinabulin (RP2D), the most common AEs 
regardless of causality were diarrhea (58%), fatigue (52%), nausea (48%), constipation (36%), vomiting 
(34%), anorexia (34%), and hypertension (32%). Unexpectedly, a significantly lower rate of neutropenia 
(all events and events ≥ Grade 3) was observed in patients in DN arm than in docetaxel (D) arm 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 53 of 77 (p≤0.01). The use of G-CSF and the rate of docetaxel dose reduction were also lower in DN than in D 
arm.  
11.2 Nivolumab (Opdivo®) 
11.2.1 Supplier/How Supplied 
Bristol-Meyers Squibb will supply nivolumab at no charge to subjects participating in this clinical trial. 
 
The site investigator shall take responsibility for and shall take all steps to maintain appropriate records 
and ensure appropriate supply, storage, handling, distribution, and usage of investigational product in 
accordance with the protocol and any applicable laws and regulations. 
11.2.2 Product Description and Dosage Form 
Nivolumab, available in the United States as Opdivo, is a sterile, preservative-free, nonpyrogenic, clear 
to opalescent, colorless to pale-yellow liquid that may contain light (few) particles. Opdivo injection for 
IV infusion is supplied in single-dose vials. It is supplied in single-use vials of 100 mg, 10 mg/mL. 
Each mL of Opdivo solution contains nivolumab 10 mg, mannitol (30 mg), pentetic acid (0.008 mg), 
polysorbate 80 (0.2 mg), sodium chloride (2.92 mg), sodium citrate dihydrate (5.88 mg), and Water for 
Injection, USP. May contain hydrochloric acid and/or sodium hydroxide to adjust pH to 6 (BMS, 
2016). Additional details or updates may be found in the most recent Prescribing Information. 
11.2.3 Storage and Stability 
Clinical supplies must be stored in a secure, limited-access location under the storage conditions specified 
on the label. Store nivolumab under refrigeration at 2°C to 8°C (36°F to 46°F). Protect nivolumab from 
light by storing in the original package until time of use. Do not freeze or shake. For additional details 
on prepared drug storage and use time of nivolumab under room temperature/light and refrigeration, 
please refer to the BMS-936558 (nivolumab) Investigator Brochure section for “Recommended Storage 
and Use Conditions.” 
 
Undiluted Nivolumab Injection and Diluted Nivolumab Injection in the IV Container.  
The administration of nivolumab infusion must be completed within 24 hours of preparation. If not 
used immediately, the infusion solution may be stored under refrigeration conditions (2° to 8°C, 36° to 
46°F) for up to 24 hours, and a maximum of 8 hours of the total 24 hours can be at room temperature 
(20° to 25°C, 68° to 77°F) and room light. The maximum 8-hour period under room temperature and 
room light conditions includes the product administration period. 
11.2.4 Handling and Disposal 
Preparation should be performed by trained personnel in accordance with good practices rules, 
especially with respect to asepsis. Please refer to the Investigator Brochure for nivolumab handling 
instructions. 
 
After final drug reconciliation, unused nivolumab vials should be disposed at the site following 
procedures for the disposal of anticancer drugs. 
11.2.5 Dispensing 
Nivolumab must be dispensed only from official study sites and to eligible subjects under the 
supervision of the site investigator. Clinical supplies may not be used for any purpose other than that 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 54 of 77 stated in the protocol. The site investigator shall take responsibility for and shall take all steps to 
maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage 
of investigational product in accordance with the protocol and any applicable laws and regulations. 
11.2.6 Administration 
Nivolumab is to be administered as an IV infusion through a 0.2-micron to 1.2-micron pore size, low-
protein binding polyethersulfone membrane in-line filter at the protocol-specified doses and infusion 
times. It is not to be administered as an IV push or bolus injection. Nivolumab injection can be infused 
undiluted (10 mg/mL) or diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, 
USP to protein concentrations as low as 0.35 mg/mL. During drug product preparation and handling, 
vigorous mixing or shaking is to be avoided. Care must be taken to assure sterility of the prepared 
solution as the product does not contain any antimicrobial preservative or bacteriostatic agent.  No 
incompatibilities between nivolumab and polyvinyl chloride (PVC) and non-PVC/non-DEHP (di(2-
ethylhexyl)phthalate) containers/IV components or glass bottles have been observed.  
11.2.7 Adverse Events 
Please refer to the nivolumab Investigator’s Brochure for a complete list of adverse events.  
 
Potential safety concerns and recommended management guidelines regarding pulmonary toxicities, GI 
toxicities, hepatotoxicities, endocrinopathies, dermatologic toxicities, and other toxicities of concern 
are summarized below. Management algorithms are found in Appendix 1.  
 
The overall safety experience with nivolumab is based on experience as either monotherapy or in 
combination with other therapeutics. In general, for monotherapy, the safety profile is similar across 
tumor types. The only exception is pulmonary inflammation AEs, which may be numerically greater in 
subjects with NSCLC, possibly because in some cases, it can be difficult to distinguish between 
nivolumab-related and unrelated causes of pulmonary symptoms and radiographic changes.  
 
Most common adverse reactions (≥20%) in patients were:  
 Nivolumab as a single agent: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, 
asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper 
respiratory tract infection, pyrexia, headache, abdominal pain. 
 Nivolumab with ipilimumab for melanoma: fatigue, rash, diarrhea, nausea, pyrexia, vomiting, 
and dyspnea. 
 Nivolumab with ipilimumab for renal cell carcinoma: fatigue, rash, diarrhea, musculoskeletal 
pain, pruritus, nausea, cough, pyrexia, arthralgia and decreased appetite. 
11.3 Ipilimumab (Yervoy™) 
11.3.1 Supplier/How Supplied 
Bristol-Meyers Squibb will supply ipilimumab at no charge to subjects participating in this clinical 
trial. 
 
The site investigator shall take responsibility for and shall take all steps to maintain appropriate records 
and ensure appropriate supply, storage, handling, distribution, and usage of investigational product in 
accordance with the protocol and any applicable laws and regulations. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 55 of 77 11.3.2 Product Description and Dosage Form 
Ipilimumab, available in the United States as Yervoy, is a sterile, preservative-free, clear to slightly 
opalescent, colorless to pale yellow solution for IV infusion, which may contain a small amount of 
visible translucent-to-white, amorphous ipilimumab particulates. It is supplied in single-use vials of 200 
mg/40 mL. Each milliliter contains 5 mg of ipilimumab and the following inactive ingredients: 
diethylene triamine pentaacetic acid (DTPA) (0.04 mg), mannitol (10 mg), polysorbate 80 (vegetable 
origin) (0.1 mg), sodium chloride (5.85 mg), tris hydrochloride (3.15 mg), and Water for Injection, USP 
at a pH of 7 (BMS 2015). 
11.3.3 Storage and Stability  
Ipilimumab Injection, 200 mg/40 mL (5 mg/mL), must be stored refrigerated (2°C to 8°C) and 
protected from light. Ipilimumab injection must not be frozen. Partially used vials or empty vials of 
ipilimumab injection should be discarded at the site according to appropriate drug disposal procedures.  
 
Ipilimumab injection may be stored undiluted (5 mg/mL) or following dilution in 0.9% Sodium 
Chloride Injection, USP or 5% Dextrose Injection in PVC, non-PVC/non-DEHP or glass containers for 
up to 24 hours (at 2°C to 8°C) or RT/RL.  
 
Recommended safety measures for preparation and handling include protective clothing, gloves, and 
safety cabinets. 
11.3.4 Handling and Disposal 
Preparation should be performed by trained personnel in accordance with good practices rules, 
especially with respect to asepsis. Please refer to the Investigator Brochure for ipilimumab handling 
instructions. 
 
After final drug reconciliation, unused ipilimumab vials should be disposed at the site following 
procedures for the disposal of anticancer drugs. 
11.3.5 Dispensing 
Ipilimumab must be dispensed only from official study sites and to eligible subjects under the 
supervision of the site investigator. Clinical supplies may not be used for any purpose other than that 
stated in the protocol. The site investigator shall take responsibility for and shall take all steps to 
maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage 
of investigational product in accordance with the protocol and any applicable laws and regulations. 
11.3.6 Adverse Events 
Please refer to the ipilimumab Investigator’s Brochure or prescribing information for a complete list of 
adverse events.  
 
Blockade of CTLA-4 by ipilimumab leads to T-cell activation, with the potential for clinical 
inflammatory AEs primarily involving the skin (dermatitis/pruritus), GI tract (diarrhea/colitis), liver 
(hepatitis), endocrine glands (eg, hypophysitis and adrenal or thyroid abnormalities), and other less 
frequent organs (eg, uveitis/episcleritis). The majority of these inflammatory AEs initially manifested 
during treatment; however, a minority occurred weeks to months after discontinuation of ipilimumab. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 56 of 77 The majority of the inflammatory AEs is reversible with the guidance issued in Appendix 1. In rare 
cases, these inflammatory AEs may be fatal. 
 
The most common adverse reactions (≥5%) are fatigue, diarrhea, pruritus, rash, and colitis. Additional 
common adverse reactions at the 10 mg/kg dose (≥5%) include nausea, vomiting, headache, weight 
loss, pyrexia, decreased appetite, and insomnia. 
 
12. ADVERSE EVENTS 
12.1 Definitions 
12.1.1 Adverse Event (AE) 
An AE is any untoward medical occurrence whether or not considered related to the study drug that 
appears to change in intensity during the course of the study. The following are examples of AEs:  
 Unintended or unfavorable sign or symptom 
 A disease temporally associated with participation in the protocol 
 An intercurrent illness or injury that impairs the well-being of the subject 
 
Abnormal laboratory values or diagnostic test results constitute AEs only if they induce clinical signs or 
symptoms or require treatment or further diagnostic tests   
 
Hospitalization for elective surgery or routine clinical procedures that are not the result of an AE (e.g., 
surgical insertion of central line) should not be recorded as an AE.  
 
Disease progression should not be recorded as an AE, unless it is attributable to the study regimen by the 
site investigator. 
12.1.2 Immune-related Adverse Events (irAEs) 
irAE’s are defined as any treatment-related AE that is inflammatory in nature, is consistent with the 
mechanism of action of immunotherapy and generally medically manageable with topical and/or 
systemic immunosuppressants. 
12.1.3 Serious Adverse Event (SAE) 
An SAE is an adverse event that: 
 Results in death.  
 Is life-threatening (defined as an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more 
severe) 
 Requires inpatient hospitalization for >24 hours or prolongation of existing hospitalization. 
NOTE: Hospitalization for anticipated or protocol specified procedures such as administration 
of chemotherapy, central line insertion, metastasis interventional therapy, resection of primary 
tumor, or elective surgery, will not be considered serious adverse events. 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly or birth defect 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 57 of 77 o Is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention (e.g., medical, 
surgical) to prevent one of the other serious outcomes listed in the definition above). 
Examples of such events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions not resulting in 
hospitalization; or the development of drug dependency or drug abuse.  
12.1.4 Unexpected Adverse Event 
For this study, an AE is considered unexpected when it varies in nature, intensity or frequency from 
information provided in the current IB, package insert, or when it is not included in the informed 
consent document as a potential risk. Unexpected also refers to AEs that are mentioned in the IB as 
occurring with a class of drugs or are anticipated from the pharmacological properties of the drug but are 
not specifically mentioned as occurring with the particular drug under investigation.   
12.1.5 Relatedness 
AEs will be categorized according to the likelihood that they are related to the study drug(s). 
Specifically, they will be categorized using the following terms:  
Unrelated The Adverse Event is not related  to the drug(s)  
Unlikely The Adverse Event is doubtfully related  to the drug(s)  
Possible The Adverse Event may be related  to the drug(s)  
Probable The Adverse Event is  likely related  to the drug(s)  
Definite The Adverse Event is clearly related  to the drug(s)  
 
12.2 Reporting 
12.2.1 Adverse Events and Immune Related Adverse Events 
 AEs and irAEs will be recorded from time of registration until 100 days after discontinuation of 
study drug(s) or until a new anti-cancer treatment starts, whichever occurs first. 
 AEs will be recorded whether or not they are considered related to the study drug(s).   
 All AEs/ irAEs will be recorded in the subject’s medical record and on the appropriate study 
specific eCRF form within the EDC system. 
 Asymptomatic laboratory abnormalities that do not require treatment will not be collected as 
adverse events. 
 All patients experiencing SAE/AEs or serious irAEs/ irAEs resulting in permanent 
discontinuation from the study regardless of seriousness or relationship to study drug or 
experiencing treatment-related toxicities of grade 2 at the End of Treatment visit should be 
followed-up monthly until all the toxicities are resolved to grade 1, or stabilized, or patient 
receives other anti-cancer therapy, whichever occurs first. 
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 58 of 77 12.2.2 Serious Adverse Events (SAEs) 
12.2.2.1 Site Requirements for Reporting SAEs to Big Ten CRC Administrative Headquarters 
 SAEs/ serious irAEs will be reported from time of registration until 100 days after 
discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever occurs 
first.  
 SAEs/ serious irAEs will be reported on the SAE Submission Form and entered in the SAE tab 
in the EDC system  within 1 business day  of discovery of the event.   
 SAEs include events related and unrelated to the study drug(s).  
 All SAEs/ serious irAEs will be recorded in the subject’s medical record and on the appropriate 
study specific eCRF form within the EDC system.   
 All SAEs regardless of relation to study drug and serious irAEs will be followed until resolution 
to ≤ Grade 1 or baseline and/or deemed clinically insignificant and/or until a new anti-cancer 
treatment starts, whichever occurs first. 
 
The site will submit the completed SAE Submission Form (see Documents/Info tab of the EDC) to Big 
Ten CRC AHQ within 1 business day of discovery of the event.  The form will be sent electronically to 
Big Ten CRC AHQ at SAFETY@hoosiercancer.org .  The site investigator is responsible for informing 
the IRB and/or other local regulatory bodies of the SAE as per local requirements. 
 
The original copy of the SAE Submission Form and the email correspondence or fax confirmation sheet 
must be kept within the study file at the study site. 
 
If an ongoing SAE changes in intensity or causal relationship to the investigational product, or if new 
information becomes available, a follow-up SAE report should be sent electronically to Big Ten CRC 
AHQ at SAFETY@hoosiercancer.org within 1 business day. Once the SAE has resolved, sites must 
submit a follow up SAE Submission Form within a reasonable timeframe to Big Ten CRC AHQ at 
SAFETY@hoosiercancer.org . 
 
12.3 Site Requirements for Reporting Pregnancy to Big Ten CRC Administrative Headquarters 
A female patient of childbearing potential must be instructed to immediately inform the Investigator if 
she becomes pregnant during the study. Pregnancies occurring up to 23 weeks after the completion of 
treatment with plinabulin must also be reported to the Investigator. The Investigator should counsel the 
patient; discuss the risks of continuing with the pregnancy and the possible effects on the fetus 
(congenital anomalies). Monitoring of the patient will continue until conclusion of the pregnancy. 
Patients who become pregnant while on study will be discontinued from the study treatment and all 
safety follow up procedures will be performed.  
Pregnancy occurring up to 31 weeks after the completion of plinabulin in the partner of a patient 
participating in the study should also be immediately reported to the Investigator and the Sponsor. The 
partner should be counseled and followed as described above. Pregnant partners of male participants 
will also be followed until the conclusion of the pregnancy. 
Pregnancy is not an SAE. However, the outcome of a pregnancy must be reported to detect a potential 
SAE (congenital anomaly, premature birth, or birth defect). All pregnancies must be initially reported 
and follow-up information must be provided on the pregnancy form. The timeframe to report a 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 59 of 77 pregnancy to Big Ten CRC AHQ is from start of study drug up to 23 weeks (female) or 31 weeks (male) 
after the last dose of study drug. If the outcome of the pregnancy meets any SAE criterion (including 
stillbirth, neonatal death, spontaneous abortion, or congenital anomaly – including that in an aborted 
fetus) the Investigator must follow the procedures for reporting SAEs. Any neonatal death occurring 30 
days after birth will be reported as an SAE. If a pregnancy occurs in the female partner of a male patient, 
the Investigator will then (and only then) also be required to obtain her consent to hold her data on file. 
If the female partner is unwilling to sign the consent, her data may not be held in the safety database. 
However, this will not affect the ability of the male patient to continue in the study. 
12.3.1.1 Big Ten CRC AHQ Requirements for Reporting SAEs to BeyondSpring Pharmaceuticals 
Big Ten CRC AHQ will report SAEs to Beyond Spring Pharmaceuticals within 1 business day  of 
receipt of the SAE Reporting Form from a site.  Follow-up information will be provided to Beyond 
Spring Pharmaceuticals as it is received from a site.  
 
Contact information for sending SAE information to BeyondSpring Pharmaceuticals: 
 
SAE Email Address:  ICON-Safety-CentralReceipt@iconplc.com    
SAE Facsimile Number (when e-mail is offline): 215-616-3096 
12.3.1.2 Big Ten CRC AHQ Requirements for Reporting SAEs to Bristol Myers-Squibb 
Big Ten CRC AHQ will report all SAEs to Bristol Myers-Squibb within 1 business day  of receipt of the 
SAE Reporting Form from a site.  Follow-up information will be provided to Bristol Myers-Squibb as it 
is received from a site. 
 
Contact information for sending SAE information to BMS: 
 
SAE Email Address:  Worldwide.Safety@BMS.com 
SAE Facsimile Number:  609-818-3804 
12.3.1.3 Sponsor-Investigator Responsibilities 
Big Ten CRC AHQ will send a SAE summary to the sponsor-investigator within 1 business day  of 
receipt of SAE Submission Form from a site.  The sponsor-investigator will promptly review the SAE 
summary and assess for expectedness and relatedness. 
12.3.1.4 Big Ten CRC AHQ Responsibilities for Reporting SAEs to FDA 
Big Ten CRC AHQ has been designated to manage the Investigational New Drug Application (IND) 
associated with this protocol on behalf of the sponsor-investigator.  Big Ten CRC AHQ will cross-
reference this submission to Beyond Spring Pharmaceuticals’s parent IND at the time of submission.  
Additionally, Big Ten CRC AHQ will submit a copy of these documents to Beyond Spring 
Pharmaceuticals at the time of submission to FDA. 
 
Big Ten CRC AHQ will be responsible for all communication with the FDA in accordance with 
21CFR312 which includes but is not limited to the 7 and 15 Day Reports, as well as an Annual Progress 
Report. Additionally, Big Ten CRC AHQ will submit a copy of these reports to Beyond Spring 
Pharmaceuticals at the time of submission to FDA. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 60 of 77 12.3.1.5 IND Safety Reports Unrelated to this Trial 
Beyond Spring Pharmaceuticals will provide Big Ten CRC AHQ with IND safety reports from external 
studies that involve the study drug(s) per their guidelines. Big Ten CRC AHQ will forward the safety 
reports to the sponsor-investigator who will review these reports and determine if revisions are needed 
to the protocol or consent.  Big Ten CRC AHQ will forward these reports to participating sites within 1 
business day  of receiving the sponsor-investigator’s review. Based on the sponsor-investigator’s 
review, applicable changes will be made to the protocol and informed consent document (if required). 
All IND safety reports will also be made available to sites via the EDC system. 
 
Upon receipt from Big Ten CRC AHQ, site investigators (or designees) are responsible for submitting 
these safety reports to their respective IRBs, as per their IRB policies. 
 
13. STATISTICAL METHODS 
13.1 Study Design 
This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single arm part (Phase 
II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and 
who are candidates for second-line therapy. 
13.2 Endpoints 
13.2.1 Definition of Primary Endpoint 
 The safety endpoints for Phase I are the incidence of grade 3 and 4 toxicities as defined by the 
NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4 
 PFS in the Phase II part of the study 
13.2.2 Definition of Secondary Endpoints 
 ORR in the Phase II part of the study. 
 CBR: complete response, partial response, or stable disease. 
 6-month PFS. 
 OS and 1-year OS. 
13.3 Sample Size and Accrual 
For the Phase I part of the study, between 9 and 15 patients will be enrolled over a period of 6-9 months. 
 
For the Phase II portion of the study, there will be one treatment arm with a total of 26 patients. Patients 
who receive plinabulin at RP2D level in phase I dose-escalation will count towards the 26 patients. The 
RP2D for plinabulin is 30 mg/m2. Accrual will be over 18 months.  
 
Patients in the phase I part who withdraw from the study before the last day of Cycle 2, for reasons other 
than DLT, will be replaced. The replacement patient will be dosed at the same dose level as the patient 
who withdrew.  
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 61 of 77 For the Phase II portion of the study, there will be one treatment arm, and PFS will be the primary 
outcome. In previous studies, without plinabulin, the median survival was 1.5 months ( Ready et al 
2020). It is anticipated to be able to detect, with 80% power, an increase in PFS from 1.5 to 3.5 months 
(a 2 month increase), with a two-sided 5% level test of survival. Assuming an accrual period of 12 
months and an additional 1 year of follow-up time, this increase could be detected by accruing 26 
patients. Patients who receive plinabulin at RP2D level in phase I dose-escalation will count towards the 
26 patients and will be included in the efficacy analysis.  
 
13.4 Analysis Populations 
Safety Population : all patients who receive at least 1 cycle or have at least 1 post-dose safety 
assessment. 
DLT Evaluable Population : all patients in the dose-escalation part who receive 2 cycles of nivolumab, 
ipilimumab and plinabulin. Patients who experience a DLT within the first 42 days of treatment and 
drop out of the study will be considered evaluable for DLT and will not be replaced. Patients who drop 
out of the study for reasons other than DLT will be considered not evaluable and will be replaced.  
Efficacy Evaluable Population : all patients who receive RP2D of plinabulin and meet the following 2 
criteria will be considered evaluable for efficacy: 
 patients who receive at least 2 cycles of therapy 
 patients who have at least 1 on-study disease assessment or who expire prior to the first planned 
on-study disease assessment. 
13.5 Assessment of Safety 
13.5.1 Adverse Events 
All treatment emergent AEs will be graded according to National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) version 4, and grouped by the Medical 
Dictionary for Regulatory Activities (MedDRA) Preferred Term and System Organ Class, and 
summarized by worst grade severity per patient. 
Treatment emergent AEs are those events that occur after first administration of any study therapy 
through 100 days post last dose of any active study therapy, and/or any treatment-related AEs, 
regardless of the onset date. 
13.5.2 Deaths 
Treatment emergent deaths are those deaths within 30 days of last dose of any study therapy. Early 
deaths are those deaths within 60 days of the first dose of study therapy. 
Treatment emergent and/or early deaths will be tabulated and summarized by treatment groups. 
13.5.3 Other Serious Adverse Events 
SAEs are those events that result in death, are life-threatening, require or prolong inpatient 
hospitalization, result in persistent or significant disability/incapacity, or result in a congenital anomaly 
or birth defect in the fetus of a study patient pregnancy. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 62 of 77 All treatment emergent SAEs will be tabulated and summarized by MedDRA preferred term and 
treatment groups. 
13.5.4 Other Significant Adverse Events 
All treatment emergent AEs leading to withdrawal of study therapy will be tabulated and summarized by 
CTCAE v4.0 MedDRA preferred term and treatment groups. 
13.6 Data Analysis Plans 
13.6.1 Analysis Plans for Primary Objective 
Progression-free Survival (PFS) 
PFS is time from registration to the first documented tumor progression, or death due to any cause 
whichever occurred first. PFS time of any living patient with no documented progression, or any patient 
starting other cytotoxic and/or cytostatic therapies, will be censored at the date of last evaluable disease 
assessment on-study. PFS time of patients with no evaluable disease assessment on-study will be 
censored at registration. 
 
Distributions of PFS times will be estimated using the Kaplan-Meier product-limit method. The median 
PFS times with two-sided 95% CIs will be estimated. In addition, Royston-Parmar models will be used 
to visualize the hazard rate functions and the survival functions ( Royston and Parmar 2002, Lambert and 
Royston 2009 ). For the definition of disease progression, refer to RECIST version 1.1. 
13.6.2 Analysis Plans for Secondary Objectives 
Overall Survival (OS): OS time is from registration to death due to any cause. OS time of living 
patients will be censored at the date last known alive. Distributions of OS times will be estimated using 
the Kaplan-Meier product-limit method. The median OS times with two-sided 95% confidence intervals 
(CIs) will be estimated. In addition, Royston-Parmar models will be used to visualize the hazard rate 
functions and the survival functions ( Royston and Parmar 2002, Lambert and Royston 2009 ). 
 
Objective Response Rate (ORR): ORR to protocol treatment will be evaluated by RECIST version 1.1, 
and the best overall response will be classified as complete response (CR), partial response (PR), stable 
disease, progressive disease (PD), and not evaluable (NE). ORR is defined as the proportion of patients 
with a best overall response of CR or PR, divided by the number of assigned patients.  
 
Clinical Benefit Rate (CBR): CBR is defined as the percentage of patients who achieve CR, PR and 
stable disease.  
13.7 Analysis Plans for Correlative/ Exploratory Objectives 
13.7.1 Biomarkers of Inflammation 
Levels of high sensitivity C-reactive protein [hsCRP], erythrocyte sedimentation rate [ESR], serum 
amyloid A [SAA] and haptoglobin will be measured in whole blood on day 1 of each cycle. Changes 
over time in the levels of these biomarkers will be measured using paired t-tests. Univariate analysis 
using logistic regression will be utilized to assess for an association between plinabulin use and levels of 
each of these markers. 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 63 of 77 13.7.2 Tumor Mutation Burden  
Tumor mutation burden (TMB) is a measure of the number of somatic protein-coding base substitution 
and insertion/deletion mutations occurring in a tumor specimen. TMB will be measured in mutations per 
megabase (mb). TMB levels will be divided into three groups: low (1-5 mutations/mb), intermediate (6-
19 mutations/mb), and high (≥ 20 mutations/mb). For analyses, comparisons will be made between both 
low to intermediate vs. high and low vs. intermediate to high TMB. Correlations between TMB and (1) 
PFS and (2) ORR, will be calculated using Spearman correlation formula. Linear regressions will also 
be performed using the least squares method. 
13.8 Interim Analysis/Criteria for Stopping Study 
For an early and detailed safety assessment, complete review of the AE data for the first 9 patients 
treated with plinabulin/nivolumab/ipilimumab will occur after completion of 2 cycles (6 weeks) of 
therapy. The toxicity rate (for grade 3 and 4 treatment-related events) has been observed to be around 
30% with prior studies ( Antonia et al 2016 ). If 3 or more patients experience 1 or more grade 3 or 4 
treatment-related AE, further enrollment will stop until detailed analysis of the AE data occurs. 
 
14. TRIAL MANAGEMENT 
14.1 Data and Safety Monitoring Plan (DSMP) 
The study will be conducted in accordance with Rutgers Cancer Institute of New Jersey Comprehensive 
Cancer Center DSMP. 
 
Big Ten CRC AHQ oversight activities include: 
 Review all adverse events requiring expedited reporting as defined in the protocol 
 Notify participating sites of adverse events requiring expedited reporting 
 Provide trial accrual progress, safety information, and data summary reports to the sponsor-
investigator 
 Submit data summary reports to the lead institution Data Safety Monitoring Committee for review as 
per their DSMP 
14.2 Rutgers Cancer Institute of New Jersey Data Safety Monitoring Committee  
The Rutgers CINJ DSMC will review the following: 
 Adverse event summary report 
 Audit results, if applicable 
 Data related to stopping/decision rules described in study design 
 Study accrual patterns  
 Protocol deviations 
 
The Rutgers CINJ DSMC will review study data every quarter. Documentation of DSMC reviews will 
be provided to sponsor-investigator and Big Ten CRC AHQ.  Issues of immediate concern by the 
DSMC will be brought to the attention of the sponsor-investigator and other regulatory bodies as 
appropriate.  The sponsor-investigator will work with Big Ten CRC AHQ to address the DSMC’s 
concerns.   
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 64 of 77 14.3 Data Quality Oversight Activities 
Remote validation of the EDC system data will be completed on a continual basis throughout the life 
cycle of the study.  A summary report (QC Report) of these checks together with any queries resulting 
from manual review of the eCRFs will be generated for each site and transmitted to the site and the site 
monitor. Corrections will be made by the study site personnel. 
 
Monitoring visits to the trial sites may be made periodically during the trial to ensure key aspects of the 
protocol are followed. Additional for-cause visits may occur as necessary. Source documents will be 
reviewed for verification of agreement with data entered into the EDC system.  It is important for the 
site investigator and their relevant personnel to be available for a sufficient amount of time during the 
monitoring visits or audit, if applicable. The site investigator and institution guarantee access to source 
documents by Big Ten CRC AHQ or its designee. 
 
The trial site may also be subject to quality assurance audit by BeyondSpring, Bristol Myers-Squibb or 
their designees as well as inspection by appropriate regulatory agencies. 
 
14.4 Compliance with Trial Registration and Results Posting Requirements 
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the Food and 
Drug Administration Amendments Act (FDAAA), the sponsor-investigator of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements for 
submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov . All results of primary and 
secondary objectives must be posted to CT.gov within a year of completion. The sponsor-investigator 
has delegated responsibility to Big Ten CRC AHQ for registering the trial and posting the results on 
clinicaltrials.gov. Information posted will allow subjects to identify potentially appropriate trials for 
their disease conditions and pursue participation by calling a central contact number for further 
information on appropriate trial locations and study site contact information.  
14.5 Protocol and/or Informed Consent Amendments 
Modification to the protocol or the Informed consent must be made only after consultation between an 
appropriate representative of the Big Ten CRC Administrative Headquarters and the Sponsor 
Investigator. Protocol Amendments must be drafted by Big Ten CRC Administrative Headquarters and 
initially reviewed and approved by the Sponsor Investigator. 
Once the Sponsor Investigator has approved the protocol amendment, the document must be submitted 
to the appropriate Independent Ethics Committee or Institutional Review Board for review and approval 
in accordance with institutional and Regulatory agency. IRB approval must be received in writing before 
any protocol changes can be implemented, except for changes necessary to eliminate an immediate 
hazard to study patients.  
15. DATA HANDLING AND RECORD KEEPING 
15.1 Data Management 
Big Ten CRC AHQ will serve as the Clinical Research Organization for this trial. Data will be collected 
through a web-based clinical research platform compliant with Good Clinical Practices and Federal 
Rules and Regulations. Big Ten CRC AHQ personnel will coordinate and manage data for quality 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 65 of 77 control assurance and integrity. All data will be collected and entered into the EDC system by study site 
personnel from participating institutions.   
15.2 Case Report Forms and Submission 
Generally, clinical data will be electronically captured in the EDC system and correlative results will be 
captured in the EDC system or other secure database(s). If procedures on the study calendar are 
performed for standard of care, at minimum, that data will be captured in the source document. Select 
standard of care data will also be captured in the EDC system, according to study-specific objectives. 
Please see the Data and Safety Oversight Process (DSOP) guidelines for further details.  
 
The completed dataset is housed at Big Ten CRC AHQ and is the sole property of the sponsor-
investigator’s institution. It should not be made available in any form to third parties, except for 
authorized representatives of appropriate Health/Regulatory Authorities, without written permission 
from the sponsor-investigator and Big Ten CRC AHQ. After the initial publication, the complete data 
set will be available to all Big Ten CRC institutions. 
15.3 Record Retention 
To enable evaluations and/or audits from Health Authorities/Big Ten CRC AHQ, the site investigator 
agrees to keep records, including the identity of all subjects (sufficient information to link records; e.g., 
hospital records), all original signed informed consent forms, copies of all source documents, and 
detailed records of drug disposition.  All source documents are to remain in the subject’s file and 
retained by the site investigator in compliance with local and federal regulations. No records will be 
destroyed until Big Ten CRC AHQ confirms destruction is permitted. 
15.4 Confidentiality 
There is a slight risk of loss of confidentiality of subject information.  All records identifying the 
subjects will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, 
will not be made publicly available. Information collected will be maintained on secure, password 
protected electronic systems. Paper files that contain personal information will be kept in locked and 
secure locations only accessible to the study site personnel.  
 
Subjects will be informed in writing that some organizations including the sponsor-investigator and 
his/her research associates, Big Ten CRC AHQ, BeyondSpring, Bristol Myers-Squibb, IRB, or 
government agencies, like the FDA, may inspect their medical records to verify the information 
collected, and that all personal information made available for inspection will be handled in strictest 
confidence and in accordance with local data protection laws. 
 
If the results of the study are published, the subjects’s identity will remain confidential. 
16. ETHICS 
16.1 Institutional Review Board (IRB) Approval 
The final study protocol and the final version of the informed consent form must be approved in writing 
by an IRB.  The site investigator must submit written approval by the IRB to Big Ten CRC AHQ before 
he or she can enroll subjects into the study.   
 
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 66 of 77 The site investigator is responsible for informing the IRB of any amendment to the protocol in 
accordance with local requirements.  In addition, the IRB must approve all advertising used to recruit 
subjects for the study.  The protocol must be re-approved by the IRB as local regulations require.  
 
Progress reports and notifications of adverse events will be provided to the IRB according to local 
regulations and guidelines. 
16.2 Ethical Conduct of the Study 
The study will be performed in accordance with ethical principles originating from the Declaration of 
Helsinki. Conduct of the study will be in compliance with ICH Good Clinical Practice, and with all 
applicable federal (including 21 CFR parts 56 & 50), state, or local laws. 
16.3 Informed Consent Process 
The site investigator will ensure the subject is given full and adequate oral and written information about 
the nature, purpose, possible risks and benefits of the study.  Subjects must also be notified they are free 
to discontinue from the study at any time.  The subject should be given the opportunity to ask questions 
and allowed time to consider the information provided. 
 
The subject’s signed and dated informed consent must be obtained before conducting any procedure 
specifically for the study.  The site investigator must store the original, signed informed consent form.  
A copy of the signed informed consent form must be given to the subject. 
 
  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 67 of 77 17. REFERENCES 
Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory 
antibodies in patients with lung cancer. Cancer Res 2013;73:2381-8. 
Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated 
mouse T and B lymphocytes. Int Immunol 1996;8:765-72. 
Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in 
recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet 
Oncol. 2016;17(7):883-95.  
Aya F, Gaba L, Victoria I, et al. Ipilimumab after progression on anti-PD-1 treatment in advanced 
melanoma. Future Oncology. 2016;12(23):2683-2688.  
Bertelsen LB, Shen YY, Nielsen T, et al. Vascular effects of plinabulin (NPI-2358) and the influence on 
tumour response when given alone or combined with radiation. Int J Radiat Biol. 2011;87(11):1126-34.  
Bristol-Myers Squibb. Immune-Mediated Adverse Reactions Management Guide. 2017, Bristol-Myers 
Squibb Company. Downloaded from: http://www.opdivohcp.com/patientmanagementresources  on 25 
October 2017. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised 
RECIST guideline (version 1.1). European J Cancer. 2009;45:228-247. 
Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage 
small-cell lung cancer. N Engl J Med.  2018;379(23):2220-2229.  
Jacobsoone-Ulrich A, Jamme P, Alkeraye S, et al. Ipilimumab in anti-PD1 refractory metastatic 
melanoma: a report of eight cases. Melanoma research. 2016;26(2):153-156.  
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.  
Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and 
management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical 
practice guidelines. Chest. 2013;143(5 Suppl):e400S-e19S. 
Jhun BW, Lee KJ, Jeon K, et al. Clinical applicability of staging small cell lung cancer according to the 
seventh edition of the TNM staging system. Lung Cancer. 2013;81(1):65-70.  
Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata 
Journal 2009;9:265–90. 
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy 
in Untreated Melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34. 
Lloyd GK, Mueller P, Zippelius A, Huang L. Plinabulin: Evidence for an immune-mediated mechanism 
of action. Cancer Res 2016;76(15 Suppl):Abstract nr A07. 
Martin K, Müller P, Schreiner J, et al. The microtubule-depolymerizing agent ansamitocin P3 programs 
dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother. 2014;63(9):925-
38. 
Millward M, Mainwaring P, Mita A, et al. Phase 1 study of the novel vascular disrupting agent 
plinabulin (NPI-2358) and docetaxel. Inves New Drugs 2012 20:1065-1073.  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 68 of 77 Mita MM, Spear MA, Yee LK, et al. Phase 1 first-in-Human trial of the vascular disrupting agent 
Plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res  2010;16:5892-
5899. 
Mohanlal RW, LLoyd K, Huang L, Bazhenova L: Plinabulin as a novel small molecule clinical stage 
immuno-oncology agent for NSCLC. 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. 
Abstract 139. Presented February 23, 2017. 
Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug 
conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 
2014;2(8):741-55. 
Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence 
for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs 2006;17:25–31. 
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T 
cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 
2009;206:1717-25. 
Powell HA, Tata LJ, Baldwin DR, et al. Treatment decisions and survival for people with small-cell 
lung cancer. Br J Cancer. 2014;110(4):908-15.  
Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in 
recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 
2020;15(3):426-35. 
Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for 
censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat 
Med. 2002;21(15):2175-97. 
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin. 2016; 66:7-30. 
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67:7-30. 
Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy 
and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 
2005;62(3):846-53. 
Singh AV, Bandi M, Raje N et al. A novel vascular disrupting agent plinabulin triggers JNK-mediated 
apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011;117(21):5692-5700. 
U.S. National Institutes of Health. National Cancer Institute. SEER Cancer Statistics Review, 1975-
2013. 
Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced 
melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010 
Feb;11(2):155-64. 
Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after 
progression on anti-PD-1 therapy in advanced melanoma. European J Cancer.  2017;75:47-55.  
  
Big Ten Cancer Research Consortium   Clinical Study Protocol 
    BTCRC-LUN17-127  
27APR2022 Confidential Page 69 of 77 18. APPENDIX 1: ADVERSE EVENT MANAGEMENT ALGORITHMS 
These general guidelines constitute guidance to the site Investigator and may be supplemented through 
discussions with the Sponsor-Investigator by contacting the Big Ten CRC project manager. The 
guidance applies to all immuno-oncology agents and regimens. 
 
As general principle, differential diagnoses should be diligently evaluated according to standard medical 
practice. Non-inflammatory etiologies should be considered and appropriately treated. 
 
Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. The oral 
equivalent of the recommended IV doses may be considered for ambulatory patients with low-grade 
toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to 
the equivalent dose of oral corticosteroids. 
 
Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended . 
 
The frequency and severity of the related adverse events covered by these algorithms will depend on the 
immuno-oncology agent or regimen being used. 
Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 70 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 71 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 72 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 73 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 74 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 75 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 76 of 77  
 
  

Big Ten Cancer Research Consortium     Clinical Study Protocol 
        BTCRC-LUN17-127  
27APR2022 Confidential Page 77 of 77  
 
